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Drug addiction is a complex illness.  It is characterized by intense and, at times, 
uncontrollable drug craving, along with compulsive drug 
seeking and use that persist even in the face of  devastating 
consequences. This update of  the National Institute on 
Drug Abuse’s Principles of Drug Addiction Treatment is 
intended to address addiction to a wide variety of  drugs, 
including nicotine, alcohol, and illicit and prescription 
drugs. It is designed to serve as a resource for healthcare 
providers, family members, and other stakeholders trying 
to address the myriad problems faced by patients in need 
of  treatment for drug abuse or addiction. 
Addiction affects multiple brain circuits, including  
those involved in reward and motivation, learning and 
memory, and inhibitory control over behavior. That is  
why addiction is a brain disease. Some individuals are 
more vulnerable than others to becoming addicted, 
depending on the interplay between genetic makeup, age 
WN M`XW[]ZM\WLZ]O[IVLW\PMZMV^QZWVUMV\ITQVÆ]MVKM[
While a person initially chooses to take drugs, over time 
the effects of  prolonged exposure on brain functioning 
compromise that ability to choose, and seeking and 
consuming the drug become compulsive, often eluding  
a person’s self-control or willpower. 
But addiction is more than just compulsive drug taking—
it can also produce far-reaching health and social 
consequences. For example, drug abuse and addiction 
increase a person’s risk for a variety of  other mental and 
physical illnesses related to a drug-abusing lifestyle or the 
toxic effects of  the drugs themselves. Additionally, the 
dysfunctional behaviors that result from drug abuse can 
interfere with a person’s normal functioning in the family, 
the workplace, and the broader community. 
Because drug abuse and addiction have so many 
dimensions and disrupt so many aspects of  an individual’s 
life, treatment is not simple. Effective treatment programs 
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typically incorporate many components, each directed 
to a particular aspect of  the illness and its consequences. 
Addiction treatment must help the individual stop 
using drugs, maintain a drug-free lifestyle, and achieve 
productive functioning in the family, at work, and in 
society. Because addiction is a disease, most people 
cannot simply stop using drugs for a few days and be 
cured. Patients typically require long-term or repeated 
episodes of  care to achieve the ultimate goal of  sustained 
IJ[\QVMVKMIVLZMKW^MZaWN \PMQZTQ^M[1VLMML[KQMV\QÅK
research and clinical practice demonstrate the value 
of  continuing care in treating addiction, with a variety 
of  approaches having been tested and integrated in 
residential and community settings. 
As we look toward the future, we will harness new research 
ZM[]T\[WV\PMQVÆ]MVKMWN OMVM\QK[IVLMV^QZWVUMV\WV
gene function and expression (i.e., epigenetics), which 
are heralding the development of  personalized treatment 
QV\MZ^MV\QWV[<PM[MÅVLQVO[_QTTJMQV\MOZI\ML_Q\P
current evidence supporting the most effective drug abuse 
and addiction treatments and their implementation, which 
IZMZMÆMK\MLQV\PQ[O]QLM
Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse
Nearly four decades of  scientific 
research and clinical practice 
have yielded a variety of  effective 
approaches to drug addiction treatment. 
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Principles 
of Effective 
Treatment
1. Addiction is a complex but treatable 
disease that affects brain function and 
behavior. Drugs of abuse alter the brain’s structure 
and function, resulting in changes that persist long after 
drug use has ceased. This may explain why drug abusers 
are at risk for relapse even after long periods of abstinence 
and despite the potentially devastating consequences.
2. No single treatment is appropriate  
for everyone. Treatment varies depending on 
the type of drug and the characteristics of the patients. 
Matching treatment settings, interventions, and services 
to an individual’s particular problems and needs is critical 
to his or her ultimate success in returning to productive 
functioning in the family, workplace, and society.
3. Treatment needs to be readily available. 
Because drug-addicted individuals may be uncertain 
about entering treatment, taking advantage of  available 
services the moment people are ready for treatment is 
critical. Potential patients can be lost if  treatment is not 
immediately available or readily accessible. As with  
other chronic diseases, the earlier treatment is offered  
in the disease process, the greater the likelihood of   
positive outcomes.
4. Effective treatment attends to multiple 
needs of the individual, not just his  
or her drug abuse. To be effective, treatment 
must address the individual’s drug abuse and any 
associated medical, psychological, social, vocational,  
and legal problems. It is also important that treatment  
be appropriate to the individual’s age, gender, ethnicity, 
and culture.
5. Remaining in treatment for an adequate 
period of time is critical. The appropriate 
duration for an individual depends on the type and degree 
of the patient’s problems and needs. Research indicates 
that most addicted individuals need at least 3 months in 
\ZMI\UMV\\W[QOVQÅKIV\TaZML]KMWZ[\WX\PMQZLZ]O][M
and that the best outcomes occur with longer durations 
of treatment. Recovery from drug addiction is a long-
term process and frequently requires multiple episodes of 
treatment. As with other chronic illnesses, relapses to drug 
abuse can occur and should signal a need for treatment to 
be reinstated or adjusted. Because individuals often leave 
treatment prematurely, programs should include strategies 
to engage and keep patients in treatment.
6. Behavioral therapies—including 
individual, family, or group counseling—
are the most commonly used forms of 
drug abuse treatment. Behavioral therapies 
vary in their focus and may involve addressing a patient’s 
motivation to change, providing incentives for abstinence, 
building skills to resist drug use, replacing drug-using 
activities with constructive and rewarding activities, 
improving problem-solving skills, and facilitating better 
interpersonal relationships. Also, participation in group 
therapy and other peer support programs during and 
following treatment can help maintain abstinence.
7. Medications are an important element of 
treatment for many patients, especially 
when combined with counseling and 
other behavioral therapies. For example, 
methadone, buprenorphine, and naltrexone (including 
a new long-acting formulation) are effective in helping 
individuals addicted to heroin or other opioids stabilize 
their lives and reduce their illicit drug use. Acamprosate, 
LQ[]TÅZIUIVLVIT\ZM`WVMIZMUMLQKI\QWV[IXXZW^ML
for treating alcohol dependence. For persons addicted 
to nicotine, a nicotine replacement product (available 
as patches, gum, lozenges, or nasal spray) or an oral 
medication (such as bupropion or varenicline) can be 
an effective component of treatment when part of a 
comprehensive behavioral treatment program.
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8. An individual’s treatment and services 
plan must be assessed continually and 
modified as necessary to ensure that 
it meets his or her changing needs. A 
patient may require varying combinations of services and 
treatment components during the course of treatment and 
recovery. In addition to counseling or psychotherapy, a 
patient may require medication, medical services, family 
therapy, parenting instruction, vocational rehabilitation, 
and/or social and legal services. For many patients, a 
continuing care approach provides the best results, with 
the treatment intensity varying according to a person’s 
changing needs.
9. Many drug-addicted individuals also 
have other mental disorders. Because 
drug abuse and addiction—both of which are mental 
disorders—often co-occur with other mental illnesses, 
patients presenting with one condition should be assessed 
for the other(s). And when these problems co-occur, 
treatment should address both (or all), including the use of 
medications as appropriate.
10. Medically assisted detoxification 
is only the first stage of addiction 
treatment and by itself does little to 
change long-term drug abuse. Although 
UMLQKITTaI[[Q[\MLLM\W`QÅKI\QWVKIV[INMTaUIVIOM\PM
acute physical symptoms of withdrawal and can, for 
some, pave the way for effective long-term addiction 
\ZMI\UMV\LM\W`QÅKI\QWVITWVMQ[ZIZMTa[]NÅKQMV\\WPMTX
addicted individuals achieve long-term abstinence. Thus, 
patients should be encouraged to continue drug treatment 
NWTTW_QVOLM\W`QÅKI\QWV5W\Q^I\QWVITMVPIVKMUMV\IVL
incentive strategies, begun at initial patient intake, can 
improve treatment engagement.
11. Treatment does not need to be 
voluntary to be effective. Sanctions or 
enticements from family, employment settings, and/or the 
KZQUQVITR][\QKM[a[\MUKIV[QOVQÅKIV\TaQVKZMI[M\ZMI\UMV\
entry, retention rates, and the ultimate success of drug 
treatment interventions.
12. Drug use during treatment must be 
monitored continuously, as lapses 
during treatment do occur. Knowing their 
drug use is being monitored can be a powerful incentive 
for patients and can help them withstand urges to use 
drugs. Monitoring also provides an early indication of a 
return to drug use, signaling a possible need to adjust an 
individual’s treatment plan to better meet his or her needs. 
13. Treatment programs should test 
patients for the presence of HIV/AIDS, 
hepatitis B and C, tuberculosis, and 
other infectious diseases, as well 
as provide targeted risk-reduction 
counseling, linking patients to 
treatment if necessary. Typically, drug abuse 
treatment addresses some of the drug-related behaviors 
that put people at risk of infectious diseases. Targeted 
counseling focused on reducing infectious disease risk 
can help patients further reduce or avoid substance-
related and other high-risk behaviors. Counseling can 
also help those who are already infected to manage their 
illness. Moreover, engaging in substance abuse treatment 
can facilitate adherence to other medical treatments. 
Substance abuse treatment facilities should provide onsite, 
rapid HIV testing rather than referrals to offsite testing—
research shows that doing so increases the likelihood 
that patients will be tested and receive their test results. 
Treatment providers should also inform patients that 
highly active antiretroviral therapy (HAART) has proven 
effective in combating HIV, including among drug-
abusing populations, and help link them to HIV treatment 
if they test positive.
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1. Why do drug-addicted persons keep 
using drugs?
Nearly all addicted individuals believe at the outset that 
they can stop using drugs on their own, and most try 
to stop without treatment. Although some people are 
successful, many attempts result in failure to achieve long-
term abstinence. Research has shown that long-term drug 
abuse results in changes in the brain that persist long after 
a person stops using drugs. These drug-induced changes 
in brain function can have many behavioral consequences, 
including an inability to exert control over the impulse 
\W][MLZ]O[LM[XQ\MIL^MZ[MKWV[MY]MVKM[¸\PMLMÅVQVO
characteristic of  addiction. 
Long-term drug use results in significant 
changes in brain function that can  
persist long after the individual stops 
using drugs. 
Understanding that addiction has such a fundamental 
JQWTWOQKITKWUXWVMV\UIaPMTXM`XTIQV\PMLQNÅK]T\a
of  achieving and maintaining abstinence without 
treatment. Psychological stress from work, family problems, 
psychiatric illness, pain associated with medical problems, 
social cues (such as meeting individuals from one’s drug-
using past), or environmental cues (such as encountering 
streets, objects, or even smells associated with drug abuse) 
can trigger intense cravings without the individual even 
being consciously aware of  the triggering event. Any 
one of  these factors can hinder attainment of  sustained 
abstinence and make relapse more likely. Nevertheless, 
research indicates that active participation in treatment is 
IVM[[MV\QITKWUXWVMV\NWZOWWLW]\KWUM[IVLKIVJMVMÅ\
even the most severely addicted individuals.
Frequently Asked 
QuestionsTreatment varies depending on the 
type of  drug and the characteristics 
of  the patient. The best programs 
provide a combination of  therapies 
and other services.
9combination of  treatments will vary depending on the 
patient’s individual needs and, often, on the types of  drugs 
they use. 
Drug addiction treatment can include 
medications, behavioral therapies, or  
their combination. 
Treatment medications, such as methadone, 
buprenorphine, and naltrexone (including a new long-
acting formulation), are available for individuals addicted 
to opioids, while nicotine preparations (patches, gum, 
lozenges, and nasal spray) and the medications varenicline 
and bupropion are available for individuals addicted to 
\WJIKKW,Q[]TÅZIUIKIUXZW[I\MIVLVIT\ZM`WVMIZM
medications available for treating alcohol dependence,1 
which commonly co-occurs with other drug addictions, 
including addiction to prescription medications. 
Treatments for prescription drug abuse tend to be 
similar to those for illicit drugs that affect the same brain 
systems. For example, buprenorphine, used to treat heroin 
addiction, can also be used to treat addiction to opioid 
pain medications. Addiction to prescription stimulants, 
which affect the same brain systems as illicit stimulants like 
cocaine, can be treated with behavioral therapies, as there 
are not yet medications for treating addiction to these 
types of  drugs. 
Behavioral therapies can help motivate people to 
participate in drug treatment, offer strategies for coping 
with drug cravings, teach ways to avoid drugs and prevent 
relapse, and help individuals deal with relapse if  it 
occurs. Behavioral therapies can also help people improve 
communication, relationship, and parenting skills, as well 
as family dynamics. 
2. What is drug addiction treatment?
Drug treatment is intended to help addicted individuals 
stop compulsive drug seeking and use. Treatment can 
occur in a variety of  settings, take many different forms, 
and last for different lengths of  time. Because drug 
addiction is typically a chronic disorder characterized by 
occasional relapses, a short-term, one-time treatment is 
][]ITTaVW\[]NÅKQMV\.WZUIVa\ZMI\UMV\Q[ITWVO\MZU
process that involves multiple interventions and regular 
monitoring. 
There are a variety of  evidence-based approaches 
to treating addiction. Drug treatment can include 
behavioral therapy (such as cognitive-behavioral 
therapy or contingency management), medications, or 
\PMQZKWUJQVI\QWV<PM[XMKQÅK\aXMWN \ZMI\UMV\WZ
The best treatment programs provide a combination of  therapies  
and other services to meet the needs of  the individual patient.
Components of Comprehensive Drug Abuse Treatment
HIV/AIDS
Services
Educational
Services
Child Care
Services
Financial
Services
Medical
Services
Housing /
Transportation 
Services
Mental Health
Services
Family
Services
Vocational
Services
Legal
Services
Intake
Processing/
Assessment
Treatment Plan
Pharmacotherapy
Continuing
Care
Clinical 
and Case
Management
Behavioral 
Therapy and 
Counseling
Substance Use
Monitoring
Self-Help/Peer 
Support Groups
8
1  Another drug, topiramate, has also shown promise in studies and is sometimes prescribed (off-label) 
for this purpose although it has not received FDA approval as a treatment for alcohol dependence.
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3. How effective is drug addiction 
treatment?
In addition to stopping drug abuse, the goal of  treatment 
is to return people to productive functioning in the family, 
workplace, and community. According to research that 
tracks individuals in treatment over extended periods, 
most people who get into and remain in treatment stop 
using drugs, decrease their criminal activity, and improve 
their occupational, social, and psychological functioning. 
For example, methadone treatment has been shown to 
increase participation in behavioral therapy and decrease 
both drug use and criminal behavior. However, individual 
treatment outcomes depend on the extent and nature of  
the patient’s problems, the appropriateness of  treatment 
and related services used to address those problems, and 
the quality of  interaction between the patient and his or 
her treatment providers. 
Relapse rates for addiction resemble 
those of other chronic diseases such  
as diabetes, hypertension, and asthma. 
Like other chronic diseases, addiction can be managed 
successfully. Treatment enables people to counteract 
addiction’s powerful disruptive effects on the brain and 
behavior and to regain control of  their lives. The chronic 
nature of  the disease means that relapsing to drug abuse is 
not only possible but also likely, with symptom recurrence 
rates similar to those for other well-characterized chronic 
medical illnesses—such as diabetes, hypertension, and 
I[\PUI[MMÅO]ZM¹+WUXIZQ[WVWN :MTIX[M:I\M[
Between Drug Addiction and Other Chronic Illnesses”)—
that also have both physiological and behavioral 
components. 
Many treatment programs employ both individual and 
group therapies. Group therapy can provide social 
reinforcement and help enforce behavioral contingencies 
that promote abstinence and a non-drug-using lifestyle. 
Some of  the more established behavioral treatments, such 
as contingency management and cognitive-behavioral 
therapy, are also being adapted for group settings to 
QUXZW^MMNÅKQMVKaIVLKW[\MNNMK\Q^MVM[[0W_M^MZ
particularly in adolescents, there can also be a danger 
of  unintended harmful (or iatrogenic) effects of  group 
treatment—sometimes group members (especially groups 
of  highly delinquent youth) can reinforce drug use and 
thereby derail the purpose of  the therapy. Thus, trained 
counselors should be aware of  and monitor for such effects. 
Because they work on different aspects of  addiction, 
combinations of  behavioral therapies and medications 
(when available) generally appear to be more effective than 
either approach used alone.
Finally, people who are addicted to drugs often suffer from 
other health (e.g., depression, HIV), occupational, legal, 
familial, and social problems that should be addressed 
concurrently. The best programs provide a combination of  
therapies and other services to meet an individual patient’s 
needs. Psychoactive medications, such as antidepressants, 
anti-anxiety agents, mood stabilizers, and antipsychotic 
medications, may be critical for treatment success when 
patients have co-occurring mental disorders such as 
depression, anxiety disorders (including post-traumatic 
stress disorder), bipolar disorder, or schizophrenia. In 
addition, most people with severe addiction abuse multiple 
drugs and require treatment for all substances abused.
Treatment for drug abuse and addiction 
is delivered in many different settings 
using a variety of behavioral and 
pharmacological approaches.
1312
health and social costs by far more than the cost of  the 
treatment itself. Treatment is also much less expensive 
than its alternatives, such as incarcerating addicted 
persons. For example, the average cost for 1 full year 
of  methadone maintenance treatment is approximately 
$4,700 per patient, whereas 1 full year of  imprisonment 
costs approximately $24,000 per person.
Drug addiction treatment reduces  
drug use and its associated health  
and social costs.
According to several conservative estimates, every dollar 
invested in addiction treatment programs yields a return 
of  between $4 and $7 in reduced drug-related crime, 
criminal justice costs, and theft. When savings related to 
healthcare are included, total savings can exceed costs 
by a ratio of  12 to 1. Major savings to the individual and 
\W[WKQM\aIT[W[\MUNZWUNM_MZQV\MZXMZ[WVITKWVÆQK\[#
greater workplace productivity; and fewer drug-related 
accidents, including overdoses and deaths.
Unfortunately, when relapse occurs many deem treatment 
a failure. This is not the case: Successful treatment for 
addiction typically requires continual evaluation and 
UWLQÅKI\QWVI[IXXZWXZQI\M[QUQTIZ\W\PMIXXZWIKP\ISMV
for other chronic diseases. For example, when a patient is 
receiving active treatment for hypertension and symptoms 
decrease, treatment is deemed successful, even though 
symptoms may recur when treatment is discontinued. 
For the addicted individual, lapses to drug abuse do not 
indicate failure—rather, they signify that treatment needs 
to be reinstated or adjusted, or that alternate treatment 
Q[VMMLML[MMÅO]ZM¹?PaQ[)LLQK\QWV<ZMI\UMV\
Evaluated Differently?”).
4. Is drug addiction treatment worth 
its cost?
Substance abuse costs our Nation over $600 billion 
annually and treatment can help reduce these costs. Drug 
addiction treatment has been shown to reduce associated 
8
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pressure from the criminal justice system, child protection 
services, employers, or family. Within a treatment program, 
successful clinicians can establish a positive, therapeutic 
relationship with their patients. The clinician should 
ensure that a treatment plan is developed cooperatively 
with the person seeking treatment, that the plan is 
followed, and that treatment expectations are clearly 
understood. Medical, psychiatric, and social services 
should also be available.
Whether a patient stays in treatment 
depends on factors associated with  
both the individual and the program.
Because some problems (such as serious medical or 
mental illness or criminal involvement) increase the 
likelihood of  patients dropping out of  treatment, intensive 
interventions may be required to retain them. After a 
course of  intensive treatment, the provider should ensure 
a transition to less intensive continuing care to support 
and monitor individuals in their ongoing recovery.
7. How do we get more substance-
abusing people into treatment?
1\PI[JMMVSVW_VNWZUIVaaMIZ[\PI\\PM¹\ZMI\UMV\
gap” is massive—that is, among those who need treatment 
for a substance use disorder, few receive it. In 2011, 21.6 
million persons aged 12 or older needed treatment for an 
illicit drug or alcohol use problem, but only 2.3 million 
received treatment at a specialty substance abuse facility. 
Reducing this gap requires a multipronged approach. 
Strategies include increasing access to effective treatment, 
achieving insurance parity (now in its earliest phase of  
implementation), reducing stigma, and raising awareness 
5. How long does drug addiction 
treatment usually last? 
Individuals progress through drug addiction treatment 
at various rates, so there is no predetermined length of  
treatment. However, research has shown unequivocally 
that good outcomes are contingent on adequate treatment 
length. Generally, for residential or outpatient treatment, 
participation for less than 90 days is of  limited effectiveness, 
IVL\ZMI\UMV\TI[\QVO[QOVQÅKIV\TaTWVOMZQ[ZMKWUUMVLMLNWZ
maintaining positive outcomes. For methadone maintenance, 
12 months is considered the minimum, and some opioid-
ILLQK\MLQVLQ^QL]IT[KWV\QV]M\WJMVMÅ\NZWUUM\PILWVM
maintenance for many years.
Good outcomes are contingent on  
adequate treatment length.
Treatment dropout is one of  the major problems 
encountered by treatment programs; therefore, motivational 
techniques that can keep patients engaged will also improve 
outcomes. By viewing addiction as a chronic disease and 
offering continuing care and monitoring, programs can 
succeed, but this will often require multiple episodes of  
treatment and readily readmitting patients that have relapsed.
6. What helps people stay in treatment?
Because successful outcomes often depend on a person’s 
[\IaQVOQV\ZMI\UMV\TWVOMVW]OP\WZMIXQ\[N]TTJMVMÅ\[
strategies for keeping people in treatment are critical. 
Whether a patient stays in treatment depends on factors 
associated with both the individual and the program. 
Individual factors related to engagement and retention 
typically include motivation to change drug-using behavior; 
degree of  support from family and friends; and, frequently, 
1716
among both patients and healthcare professionals of  
the value of  addiction treatment. To assist physicians in 
identifying treatment need in their patients and making 
appropriate referrals, NIDA is encouraging widespread 
use of  screening, brief  intervention, and referral to 
treatment (SBIRT) tools for use in primary care settings 
through its NIDAMED initiative. SBIRT, which evidence 
shows to be effective against tobacco and alcohol use—
and, increasingly, against abuse of  illicit and prescription 
drugs—has the potential not only to catch people before 
serious drug problems develop but also to identify people 
in need of  treatment and connect them with appropriate 
treatment providers.
8. How can family and friends make a 
difference in the life of someone 
needing treatment?
Family and friends can play critical roles in motivating 
individuals with drug problems to enter and stay in 
treatment. Family therapy can also be important, 
especially for adolescents. Involvement of  a family 
UMUJMZWZ[QOVQÅKIV\W\PMZQVIVQVLQ^QL]IT¼[\ZMI\UMV\
XZWOZIUKIV[\ZMVO\PMVIVLM`\MVL\ZMI\UMV\JMVMÅ\[
9. Where can family members go for 
information on treatment options?
Trying to locate appropriate treatment for a loved one, 
M[XMKQITTaÅVLQVOIXZWOZIU\IQTWZML\WIVQVLQ^QL]IT¼[
XIZ\QK]TIZVMML[KIVJMILQNÅK]T\XZWKM[[0W_M^MZ\PMZM
are some resources to help with this process. For example, 
NIDA’s handbook Seeking Drug Abuse Treatment: Know 
What to AskWNNMZ[O]QLIVKMQVÅVLQVO\PMZQOP\\ZMI\UMV\
program. Numerous online resources can help locate a 
local program or provide other information, including: 
 The Substance Abuse and Mental Health Services 
Administration (SAMHSA) maintains a Web site 
(findtreatment.samhsa.gov) that shows the location of  
residential, outpatient, and hospital inpatient treatment 
programs for drug addiction and alcoholism throughout 
the country. This information is also accessible by 
calling 1-800-662-HELP. 
 The National Suicide Prevention Lifeline (1-800-273-
TALK) offers more than just suicide prevention—it 
can also help with a host of  issues, including drug 
and alcohol abuse, and can connect individuals with a 
nearby professional. 
 The National Alliance on Mental Illness (nami.org) and 
Mental Health America (mentalhealthamerica.net) are 
ITTQIVKM[WN VWVXZWÅ\[MTNPMTX[]XXWZ\WZOIVQbI\QWV[
for patients and families dealing with a variety of  
UMV\ITLQ[WZLMZ[*W\PPI^M;\I\MIVLTWKITINÅTQI\M[
throughout the United States and may be especially 
helpful for patients with comorbid conditions. 
 The American Academy of  Addiction Psychiatry and 
the American Academy of  Child and Adolescent 
Psychiatry each have physician locator tools posted on 
their Web sites at aaap.org and aacap.org, respectively. 
 Faces & Voices of  Recovery (facesandvoicesofrecovery.
org), founded in 2001, is an advocacy organization for 
individuals in long-term recovery that strategizes on 
ways to reach out to the medical, public health, criminal 
justice, and other communities to promote and celebrate 
recovery from addiction to alcohol and other drugs.
 The Partnership at Drugfree.org (drugfree.org) is an 
organization that provides information and resources 
on teen drug use and addiction for parents, to help 
them prevent and intervene in their children’s drug use 
WZÅVL\ZMI\UMV\NWZIKPQTL_PWVMML[Q\<PMaWNNMZI
toll-free helpline for parents (1-855-378-4373).
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 The American Society of  Addiction Medicine (asam.
org) is a society of  physicians aimed at increasing access 
to addiction treatment. Their Web site has a nationwide 
directory of  addiction medicine professionals.
 NIDA’s National Drug Abuse Treatment Clinical Trials 
Network (drugabuse.gov/about-nida/organization/
cctn/ctn) provides information for those interested 
in participating in a clinical trial testing a promising 
substance abuse intervention; or visit clinicaltrials.gov.
 NIDA’s DrugPubs Research Dissemination Center 
(drugpubs.drugabuse.gov) provides booklets, pamphlets, 
fact sheets, and other informational resources on drugs, 
drug abuse, and treatment. 
 The National Institute on Alcohol Abuse and 
Alcoholism (niaaa.nih.gov) provides information on 
alcohol, alcohol use, and treatment of  alcohol-related 
problems (niaaa.nih.gov/search/node/treatment). 
10. How can the workplace play a role 
in substance abuse treatment?
Many workplaces sponsor Employee Assistance Programs 
(EAPs) that offer short-term counseling and/or assistance 
in linking employees with drug or alcohol problems to 
local treatment resources, including peer support/recovery 
groups. In addition, therapeutic work environments that 
provide employment for drug-abusing individuals who 
can demonstrate abstinence have been shown not only to 
promote a continued drug-free lifestyle but also to improve 
job skills, punctuality, and other behaviors necessary for 
active employment throughout life. Urine testing facilities, 
trained personnel, and workplace monitors are needed to 
implement this type of  treatment.
11. What role can the criminal justice 
system play in addressing drug 
addiction?
It is estimated that about one-half  of  State and Federal 
prisoners abuse or are addicted to drugs, but relatively 
few receive treatment while incarcerated. Initiating drug 
abuse treatment in prison and continuing it upon release 
is vital to both individual recovery and to public health 
and safety. Various studies have shown that combining 
prison- and community-based treatment for addicted 
offenders reduces the risk of  both recidivism to drug-
related criminal behavior and relapse to drug use—which, 
in turn, nets huge savings in societal costs. A 2009 study 
in Baltimore, Maryland, for example, found that opioid-
addicted prisoners who started methadone treatment 
(along with counseling) in prison and then continued it 
after release had better outcomes (reduced drug use and 
criminal activity) than those who only received counseling 
while in prison or those who only started methadone 
treatment after their release.
Individuals who enter treatment  
under legal pressure have outcomes  
as favorable as those who enter  
treatment voluntarily.
The majority of  offenders involved with the criminal 
justice system are not in prison but are under community 
supervision. For those with known drug problems, drug 
addiction treatment may be recommended or mandated 
as a condition of  probation. Research has demonstrated 
that individuals who enter treatment under legal pressure 
have outcomes as favorable as those who enter treatment 
voluntarily. 
The criminal justice system refers drug offenders into 
treatment through a variety of  mechanisms, such as 
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diverting nonviolent offenders to treatment; stipulating 
treatment as a condition of  incarceration, probation, or 
pretrial release; and convening specialized courts, or 
drug courts, that handle drug offense cases. These courts 
mandate and arrange for treatment as an alternative to 
incarceration, actively monitor progress in treatment, and 
arrange for other services for drug-involved offenders. 
The most effective models integrate criminal justice and 
drug treatment systems and services. Treatment and 
criminal justice personnel work together on treatment 
planning—including implementation of  screening, 
placement, testing, monitoring, and supervision—as 
well as on the systematic use of  sanctions and rewards. 
Treatment for incarcerated drug abusers should include 
continuing care, monitoring, and supervision after 
incarceration and during parole. Methods to achieve better 
KWWZLQVI\QWVJM\_MMVXIZWTMXZWJI\QWVWNÅKMZ[IVLPMIT\P
providers are being studied to improve offender outcomes. 
(For more information, please see NIDA’s Principles of 
Drug Abuse Treatment for Criminal Justice Populations: A 
Research-Based Guide [revised 2012].) 
12. What are the unique needs 
of women with substance 
use disorders?
Gender-related drug abuse treatment should attend 
not only to biological differences but also to social and 
MV^QZWVUMV\ITNIK\WZ[ITTWN _PQKPKIVQVÆ]MVKM\PM
motivations for drug use, the reasons for seeking treatment, 
the types of  environments where treatment is obtained, the 
treatments that are most effective, and the consequences 
of  not receiving treatment. Many life circumstances 
predominate in women as a group, which may require 
a specialized treatment approach. For example, research 
has shown that physical and sexual trauma followed by 
post-traumatic stress disorder (PTSD) is more common 
in drug-abusing women than in men seeking treatment. 
7\PMZNIK\WZ[]VQY]M\W_WUMV\PI\KIVQVÆ]MVKM\PM
treatment process include issues around how they come 
into treatment (as women are more likely than men to seek 
the assistance of  a general or mental health practitioner), 
ÅVIVKQITQVLMXMVLMVKMIVLXZMOVIVKaIVLKPQTLKIZM
13. What are the unique needs of 
pregnant women with substance  
use disorders?
Using drugs, alcohol, or tobacco during pregnancy 
exposes not just the woman but also her developing 
fetus to the substance and can have potentially 
deleterious and even long-term effects on exposed 
children. Smoking during pregnancy can increase 
risk of  stillbirth, infant mortality, sudden infant death 
syndrome, preterm birth, respiratory problems, slowed 
fetal growth, and low birth weight. Drinking during 
pregnancy can lead to the child developing fetal alcohol 
spectrum disorders, characterized by low birth weight 
and enduring cognitive and behavioral problems. 
Prenatal use of  some drugs, including opioids, may 
cause a withdrawal syndrome in newborns called 
neonatal abstinence syndrome (NAS). Babies with NAS 
are at greater risk of  seizures, respiratory problems, 
NMMLQVOLQNÅK]T\QM[TW_JQZ\P_MQOP\IVLM^MVLMI\P
Research has established the value of  evidence-based 
treatments for pregnant women (and their babies), 
including medications. For example, although no 
medications have been FDA-approved to treat opioid 
dependence in pregnant women, methadone maintenance 
combined with prenatal care and a comprehensive 
drug treatment program can improve many of  the 
detrimental outcomes associated with untreated heroin 
abuse. However, newborns exposed to methadone 
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during pregnancy still require treatment for withdrawal 
symptoms. Recently, another medication option for opioid 
dependence, buprenorphine, has been shown to produce 
fewer NAS symptoms in babies than methadone, resulting 
in shorter infant hospital stays. In general, it is important 
to closely monitor women who are trying to quit drug use 
during pregnancy and to provide treatment as needed.
14. What are the unique needs of 
adolescents with substance  
use disorders?
Adolescent drug abusers have unique needs stemming 
from their immature neurocognitive and psychosocial 
stage of  development. Research has demonstrated that 
the brain undergoes a prolonged process of  development 
IVLZMÅVMUMV\NZWUJQZ\P\PZW]OPMIZTaIL]T\PWWL
Over the course of  this developmental period, a young 
person’s actions go from being more impulsive to being 
UWZMZMI[WVMLIVLZMÆMK\Q^M1VNIK\\PMJZIQVIZMI[
most closely associated with aspects of  behavior such 
as decision-making, judgment, planning, and self-
control undergo a period of  rapid development during 
adolescence and young adulthood. 
Adolescent drug abuse is also often associated with 
other co-occurring mental health problems. These 
QVKT]LMI\\MV\QWVLMÅKQ\PaXMZIK\Q^Q\aLQ[WZLMZ),0,
WXXW[Q\QWVITLMÅIV\LQ[WZLMZIVLKWVL]K\XZWJTMU[I[
well as depressive and anxiety disorders. 
Adolescents are also especially sensitive to social cues, with 
XMMZOZW]X[IVLNIUQTQM[JMQVOPQOPTaQVÆ]MV\QITL]ZQVO
this time. Therefore, treatments that facilitate positive 
parental involvement, integrate other systems in which the 
adolescent participates (such as school and athletics), and 
recognize the importance of  prosocial peer relationships 
are among the most effective. Access to comprehensive 
assessment, treatment, case management, and family-
support services that are developmentally, culturally, and 
gender-appropriate is also integral when addressing 
adolescent addiction. 
Medications for substance abuse among adolescents may 
in certain cases be helpful. Currently, the only addiction 
medications approved by FDA for people under 18 
are over-the-counter transdermal nicotine skin patches, 
chewing gum, and lozenges (physician advice should be 
[W]OP\ÅZ[\*]XZMVWZXPQVMIUMLQKI\QWVNWZ\ZMI\QVO
opioid addiction that must be prescribed by specially 
trained physicians, has not been approved for adolescents, 
but recent research suggests it could be effective for those 
as young as 16. Studies are under way to determine the 
[INM\aIVLMNÅKIKaWN \PQ[IVLW\PMZUMLQKI\QWV[NWZ
opioid-, nicotine-, and alcohol-dependent adolescents and 
for adolescents with co-occurring disorders.
15. Are there specific drug addiction 
treatments for older adults?
With the aging of  the baby boomer generation, the 
composition of  the general population is changing 
dramatically with respect to the number of  older adults. 
Such a change, coupled with a greater history of  lifetime 
drug use (than previous older generations), different 
cultural norms and general attitudes about drug use, 
and increases in the availability of  psychotherapeutic 
medications, is already leading to greater drug use by 
older adults and may increase substance use problems 
in this population. While substance abuse in older adults 
often goes unrecognized and therefore untreated, research 
indicates that currently available addiction treatment 
programs can be as effective for them as for younger adults.
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16. Can a person become addicted 
to medications prescribed by a 
doctor? 
Yes. People who abuse prescription drugs—that is, taking 
them in a manner or a dose other than prescribed, or 
taking medications prescribed for another person—risk 
addiction and other serious health consequences. Such 
drugs include opioid pain relievers, stimulants used to treat 
ADHD, and benzodiazepines to treat anxiety or sleep 
disorders. Indeed, in 2010, an estimated 2.4 million people 
12 or older met criteria for abuse of  or dependence on 
prescription drugs, the second most common illicit drug 
use after marijuana. To minimize these risks, a physician 
(or other prescribing health provider) should screen 
patients for prior or current substance abuse problems and 
assess their family history of  substance abuse or addiction 
before prescribing a psychoactive medication and monitor 
patients who are prescribed such drugs. Physicians also 
need to educate patients about the potential risks so that 
they will follow their physician’s instructions faithfully, 
safeguard their medications, and dispose of  them 
appropriately.  
17. Is there a difference between 
physical dependence and addiction? 
Yes. Addiction—or compulsive drug use despite harmful 
consequences—is characterized by an inability to stop 
using a drug; failure to meet work, social, or family 
obligations; and, sometimes (depending on the drug), 
\WTMZIVKMIVL_Q\PLZI_IT<PMTI\\MZZMÆMK\XPa[QKIT
dependence in which the body adapts to the drug, 
requiring more of  it to achieve a certain effect (tolerance) 
IVLMTQKQ\QVOLZ]O[XMKQÅKXPa[QKITWZUMV\IT[aUX\WU[
if  drug use is abruptly ceased (withdrawal). Physical 
dependence can happen with the chronic use of  many 
drugs—including many prescription drugs, even if  taken 
as instructed. Thus, physical dependence in and of  itself  
does not constitute addiction, but it often accompanies 
ILLQK\QWV<PQ[LQ[\QVK\QWVKIVJMLQNÅK]T\\WLQ[KMZV
particularly with prescribed pain medications, for which 
the need for increasing dosages can represent tolerance 
or a worsening underlying problem, as opposed to the 
beginning of  abuse or addiction. 
18. How do other mental disorders 
coexisting with drug addiction 
affect drug addiction treatment? 
Drug addiction is a disease of  the brain that frequently 
occurs with other mental disorders. In fact, as many as 
6 in 10 people with an illicit substance use disorder also 
suffer from another mental illness; and rates are similar 
for users of  licit drugs—i.e., tobacco and alcohol. For 
\PM[MQVLQ^QL]IT[WVMKWVLQ\QWVJMKWUM[UWZMLQNÅK]T\\W
treat successfully as an additional condition is intertwined. 
Thus, people entering treatment either for a substance 
use disorder or for another mental disorder should be 
assessed for the co-occurrence of  the other condition. 
Research indicates that treating both (or multiple) illnesses 
simultaneously in an integrated fashion is generally the 
best treatment approach for these patients. 
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19. Is the use of medications like 
methadone and buprenorphine 
simply replacing one addiction with 
another? 
No. Buprenorphine and methadone are prescribed or 
administered under monitored, controlled conditions 
and are safe and effective for treating opioid addiction 
when used as directed. They are administered orally or 
[]JTQVO]ITTaQM]VLMZ\PM\WVO]MQV[XMKQÅMLLW[M[IVL
their effects differ from those of  heroin and other abused 
opioids. 
Heroin, for example, is often injected, snorted, or smoked, 
KI][QVOIVITUW[\QUUMLQI\M¹Z][PºWZJZQMN XMZQWL
of  intense euphoria, that wears off  quickly and ends in 
I¹KZI[Pº<PMQVLQ^QL]IT\PMVM`XMZQMVKM[IVQV\MV[M
craving to use the drug again to stop the crash and 
reinstate the euphoria. 
The cycle of  euphoria, crash, and craving—sometimes 
repeated several times a day—is a hallmark of  addiction 
and results in severe behavioral disruption. These 
characteristics result from heroin’s rapid onset and short 
duration of  action in the brain. 
As used in maintenance treatment, 
methadone and buprenorphine are  
not heroin/opioid substitutes. 
In contrast, methadone and buprenorphine have gradual 
onsets of  action and produce stable levels of  the drug 
in the brain. As a result, patients maintained on these 
medications do not experience a rush, while they also 
markedly reduce their desire to use opioids. 
If  an individual treated with these medications 
tries to take an opioid such as heroin, the euphoric 
effects are usually dampened or suppressed. Patients 
undergoing maintenance treatment do not experience 
the physiological or behavioral abnormalities from 
ZIXQLÆ]K\]I\QWV[QVLZ]OTM^MT[I[[WKQI\ML_Q\PPMZWQV
use. Maintenance treatments save lives—they help to 
stabilize individuals, allowing treatment of  their medical, 
psychological, and other problems so they can contribute 
effectively as members of  families and of  society. 
20. Where do 12-step or self-help 
programs fit into drug addiction 
treatment? 
Self-help groups can complement and extend the 
effects of  professional treatment. The most prominent 
[MTNPMTXOZW]X[IZM\PW[MINÅTQI\ML_Q\P)TKWPWTQK[
Anonymous (AA), Narcotics Anonymous (NA), and 
Cocaine Anonymous (CA); all of  which are based on the 
12-step model. Most drug addiction treatment programs 
encourage patients to participate in self-help group 
therapy during and after formal treatment. These groups 
can be particularly helpful during recovery, offering an 
added layer of  community-level social support to help 
people achieve and maintain abstinence and other healthy 
lifestyle behaviors over the course of  a lifetime. 
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21. Can exercise play a role in the 
treatment process? 
Yes. Exercise is increasingly becoming a component of  
many treatment programs and has proven effective, when 
combined with cognitive-behavioral therapy, at helping 
XMWXTMY]Q\[UWSQVO-`MZKQ[MUIaM`MZ\JMVMÅKQITMNNMK\[
by addressing psychosocial and physiological needs that 
nicotine replacement alone does not, by reducing negative 
feelings and stress, and by helping prevent weight gain 
following cessation. Research to determine if  and how 
exercise programs can play a similar role in the treatment 
of  other forms of  drug abuse is under way. 
22. How does drug addiction treatment 
help reduce the spread of HIV/
AIDS, hepatitis C (HCV), and other 
infectious diseases? 
Drug-abusing individuals, including injecting and non-
injecting drug users, are at increased risk of  human 
QUU]VWLMÅKQMVKa^QZ][01>PMXI\Q\Q[+^QZ][
(HCV), and other infectious diseases. These diseases 
are transmitted by sharing contaminated drug injection 
equipment and by engaging in risky sexual behavior 
sometimes associated with drug use. Effective drug abuse 
treatment is HIV/HCV prevention because it reduces 
activities that can spread disease, such as sharing injection 
equipment and engaging in unprotected sexual activity. 
Counseling that targets a range of  HIV/HCV risk 
behaviors provides an added level of  disease prevention. 
Drug abuse treatment is HIV and  
HCV prevention. 
Injection drug users who do not enter treatment are up to 
six times more likely to become infected with HIV than 
those who enter and remain in treatment. Participation in 
treatment also presents opportunities for HIV screening 
and referral to early HIV treatment. In fact, recent 
research from NIDA’s National Drug Abuse Treatment 
Clinical Trials Network showed that providing rapid 
onsite HIV testing in substance abuse treatment facilities 
increased patients’ likelihood of  being tested and of  
receiving their test results. HIV counseling and testing are 
key aspects of  superior drug abuse treatment programs 
and should be offered to all individuals entering treatment. 
Greater availability of  inexpensive and unobtrusive rapid 
HIV tests should increase access to these important aspects 
of  HIV prevention and treatment.
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Drug Addiction 
Treatment in the 
United States
Drug addiction is a complex disorder 
that can involve virtually every aspect 
of an individual’s functioning—in the 
family, at work and school, and in the 
community. Because of  addiction’s complexity and 
pervasive consequences, drug addiction treatment 
typically must involve many components. Some of  those 
components focus directly on the individual’s drug use; 
others, like employment training, focus on restoring the 
addicted individual to productive membership in the 
family and society (see diagram on page 8), enabling 
him or her to experience the rewards associated with 
abstinence. 
Treatment for drug abuse and addiction is delivered in 
many different settings using a variety of  behavioral 
and pharmacological approaches. In the United States, 
more than 14,500 specialized drug treatment facilities 
provide counseling, behavioral therapy, medication, case 
management, and other types of  services to persons with 
substance use disorders. 
Along with specialized drug treatment facilities, drug 
IJ][MIVLILLQK\QWVIZM\ZMI\MLQVXPa[QKQIV[¼WNÅKM[IVL
mental health clinics by a variety of  providers, including 
counselors, physicians, psychiatrists, psychologists, nurses, 
and social workers. Treatment is delivered in outpatient, 
QVXI\QMV\IVLZM[QLMV\QIT[M\\QVO[)T\PW]OP[XMKQÅK
treatment approaches often are associated with particular 
treatment settings, a variety of  therapeutic interventions or 
services can be included in any given setting. 
Because drug abuse and addiction are major public 
health problems, a large portion of  drug treatment is 
funded by local, State, and Federal governments. Private 
and employer-subsidized health plans also may provide 
coverage for treatment of  addiction and its medical 
consequences. Unfortunately, managed care has resulted 
in shorter average stays, while a historical lack of  or 
QV[]NÅKQMV\KW^MZIOMNWZ[]J[\IVKMIJ][M\ZMI\UMV\PI[
Treatment for drug abuse and 
addiction is delivered in many different 
settings, using a variety of  behavioral 
and pharmacological approaches.
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3TMJMZ0,7]\XI\QMV\LM\W`QÅKI\QWVNZWUWXQI\M[
Primary Psychiatry 1:42–52, 1996.
Long-Term Residential Treatment
Long-term residential treatment provides care 24 hours 
a day, generally in nonhospital settings. The best-known 
residential treatment model is the therapeutic community 
(TC), with planned lengths of  stay of  between 6 and 
UWV\P[<+[NWK][WV\PM¹ZM[WKQITQbI\QWVºWN \PM
individual and use the program’s entire community—
including other residents, staff, and the social context—as 
active components of  treatment. Addiction is viewed in 
the context of  an individual’s social and psychological 
LMÅKQ\[IVL\ZMI\UMV\NWK][M[WVLM^MTWXQVOXMZ[WVIT
accountability and responsibility as well as socially 
productive lives. Treatment is highly structured and can 
be confrontational at times, with activities designed to 
help residents examine damaging beliefs, self-concepts, 
and destructive patterns of  behavior and adopt new, 
more harmonious and constructive ways to interact with 
others. Many TCs offer comprehensive services, which can 
include employment training and other support services, 
WV[Q\M:M[MIZKP[PW_[\PI\<+[KIVJMUWLQÅML\W\ZMI\
individuals with special needs, including adolescents, 
women, homeless individuals, people with severe mental 
disorders, and individuals in the criminal justice system 
(see page 37).
Further Reading:
Lewis, B.F.; McCusker, J.; Hindin, R.; Frost, R.; and 
/IZÅMTL..W]ZZM[QLMV\QITLZ]O\ZMI\UMV\XZWOZIU["
Project IMPACT. In: J.A. Inciardi, F.M. Tims, and B.W. 
Fletcher (eds.), Innovative Approaches in the Treatment of 
Drug Abuse, Westport, CT: Greenwood Press, pp. 45–60, 
1993. 
curtailed the number of  operational programs. The recent 
passage of  parity for insurance coverage of  mental health 
and substance abuse problems will hopefully improve 
this state of  affairs. Health Care Reform (i.e., the Patient 
8ZW\MK\QWVIVL)NNWZLIJTM+IZM)K\WN ¹)+)ºIT[W
stands to increase the demand for drug abuse treatment 
services and presents an opportunity to study how 
QVVW^I\QWV[QV[MZ^QKMLMTQ^MZaWZOIVQbI\QWVIVLÅVIVKQVO
can improve access to and use of  them.
Types of Treatment Programs 
Research studies on addiction treatment typically have 
KTI[[QÅMLXZWOZIU[QV\W[M^MZITOMVMZIT\aXM[WZUWLITQ\QM[
Treatment approaches and individual programs continue 
to evolve and diversify, and many programs today do 
VW\Å\VMI\TaQV\W\ZILQ\QWVITLZ]OILLQK\QWV\ZMI\UMV\
KTI[[QÅKI\QWV[-`IUXTM[WN [XMKQÅKZM[MIZKPJI[ML
treatment components are described on pages 30–35. 
5W[\PW_M^MZ[\IZ\_Q\PLM\W`QÅKI\QWVIVLUMLQKITTa
UIVIOML_Q\PLZI_ITWN\MVKWV[QLMZML\PMÅZ[\[\IOMWN 
\ZMI\UMV\,M\W`QÅKI\QWV\PMXZWKM[[Ja_PQKP\PMJWLa
clears itself  of  drugs, is designed to manage the acute and 
potentially dangerous physiological effects of  stopping 
LZ]O][M)[[\I\MLXZM^QW][TaLM\W`QÅKI\QWVITWVMLWM[VW\
address the psychological, social, and behavioral problems 
associated with addiction and therefore does not typically 
produce lasting behavioral changes necessary for recovery. 
,M\W`QÅKI\QWV[PW]TL\P][JMNWTTW_MLJaINWZUIT
assessment and referral to drug addiction treatment. 
Because it is often accompanied by unpleasant and 
potentially fatal side effects stemming from withdrawal, 
LM\W`QÅKI\QWVQ[WN\MVUIVIOML_Q\PUMLQKI\QWV[
administered by a physician in an inpatient or outpatient 
[M\\QVO#\PMZMNWZMQ\Q[ZMNMZZML\WI[¹UMLQKITTaUIVIOML
withdrawal.” Medications are available to assist in the 
withdrawal from opioids, benzodiazepines, alcohol, 
nicotine, barbiturates, and other sedatives.
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Outpatient Treatment Programs
Outpatient treatment varies in the types and intensity of  
services offered. Such treatment costs less than residential 
or inpatient treatment and often is more suitable for 
people with jobs or extensive social supports. It should 
be noted, however, that low-intensity programs may offer 
little more than drug education. Other outpatient models, 
such as intensive day treatment, can be comparable 
to residential programs in services and effectiveness, 
depending on the individual patient’s characteristics and 
needs. In many outpatient programs, group counseling 
can be a major component. Some outpatient programs 
are also designed to treat patients with medical or other 
mental health problems in addition to their drug disorders. 
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outcomes in the Drug Abuse Treatment Outcome Study 
(DATOS). Psychology of Addictive Behaviors 11(4):291–
298, 1998. 
Institute of  Medicine. Treating Drug Problems. 
Washington, D.C.: National Academy Press, 1990. 
Sacks, S.; Banks, S.; McKendrick, K.; and Sacks, J.Y. 
5WLQÅML\PMZIXM]\QKKWUU]VQ\aNWZKWWKK]ZZQVOLQ[WZLMZ["
A summary of  four studies. Journal of Substance Abuse 
Treatment 34(1):112–122, 2008. 
Sacks, S.; Sacks, J.; DeLeon, G.; Bernhardt, A.; and 
;\IQVM[/5WLQÅML\PMZIXM]\QKKWUU]VQ\aNWZUMV\ITTa
QTTKPMUQKIT¹IJ][MZ[º"*IKSOZW]VL#QVÆ]MVKM[#XZWOZIU
LM[KZQX\QWV#XZMTQUQVIZaÅVLQVO[Substance Use and Misuse 
32(9):1217–1259, 1997. 
Stevens, S.J.; and Glider, P.J. Therapeutic communities: 
Substance abuse treatment for women. In: F.M. Tims, G. 
DeLeon, and N. Jainchill (eds.), Therapeutic Community: 
Advances in Research and Application, National Institute 
on Drug Abuse Research Monograph 144, NIH Pub. No. 
!·=;/W^MZVUMV\8ZQV\QVO7NÅKMXX· 
1994. 
Sullivan, C.J.; McKendrick, K.; Sacks, S.; and Banks, S.M. 
5WLQÅML\PMZIXM]\QKKWUU]VQ\aNWZWNNMVLMZ[_Q\P51+)
disorders: Substance use outcomes. American Journal of 
Drug and Alcohol Abuse 33(6):823–832, 2007.
Short-Term Residential Treatment
Short-term residential programs provide intensive but 
ZMTI\Q^MTaJZQMN \ZMI\UMV\JI[MLWVIUWLQÅML[\MX
approach. These programs were originally designed to 
treat alcohol problems, but during the cocaine epidemic 
of  the mid-1980s, many began to treat other types of  
substance use disorders. The original residential treatment 
model consisted of  a 3- to 6-week hospital-based inpatient 
treatment phase followed by extended outpatient therapy 
and participation in a self-help group, such as AA. 
Following stays in residential treatment programs, it is 
important for individuals to remain engaged in outpatient 
treatment programs and/or aftercare programs. These 
programs help to reduce the risk of  relapse once a patient 
leaves the residential setting.
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Treating Criminal Justice–Involved Drug 
Abusers and Addicted Individuals
Often, drug abusers come into contact with the criminal 
justice system earlier than other health or social systems, 
presenting opportunities for intervention and treatment 
prior to, during, after, or in lieu of  incarceration. Research 
has shown that combining criminal justice sanctions with 
drug treatment can be effective in decreasing drug abuse 
and related crime. Individuals under legal coercion tend 
to stay in treatment longer and do as well as or better 
than those not under legal pressure. Studies show that 
for incarcerated individuals with drug problems, starting 
drug abuse treatment in prison and continuing the same 
treatment upon release—in other words, a seamless 
continuum of  services—results in better outcomes: less 
drug use and less criminal behavior. More information 
on how the criminal justice system can address the 
problem of  drug addiction can be found in Principles of 
Drug Abuse Treatment for Criminal Justice Populations: A 
Research-Based Guide (National Institute on Drug Abuse, 
revised 2012).
McLellan, A.T.; Grisson, G.; Durell, J.; Alterman, A.I.; 
Brill, P.; and O’Brien, C.P. Substance abuse treatment in 
the private setting: Are some programs more effective than 
others? Journal of Substance Abuse Treatment 10:243–254, 
1993. 
Simpson, D.D.; and Brown, B.S. Treatment retention 
and follow-up outcomes in the Drug Abuse Treatment 
Outcome Study (DATOS). Psychology of Addictive 
Behaviors 11(4):294–307, 1998.
Individualized Drug Counseling
Individualized drug counseling not only focuses on 
reducing or stopping illicit drug or alcohol use; it also 
addresses related areas of  impaired functioning—such 
as employment status, illegal activity, and family/social 
relations—as well as the content and structure of  the 
patient’s recovery program. Through its emphasis on 
short-term behavioral goals, individualized counseling 
helps the patient develop coping strategies and tools to 
abstain from drug use and maintain abstinence. The 
addiction counselor encourages 12-step participation (at 
least one or two times per week) and makes referrals for 
needed supplemental medical, psychiatric, employment, 
and other services.
Group Counseling
Many therapeutic settings use group therapy to capitalize 
on the social reinforcement offered by peer discussion and 
to help promote drug-free lifestyles. Research has shown 
that when group therapy either is offered in conjunction 
with individualized drug counseling or is formatted to 
ZMÆMK\\PMXZQVKQXTM[WN KWOVQ\Q^MJMPI^QWZIT\PMZIXaWZ
contingency management, positive outcomes are achieved. 
Currently, researchers are testing conditions in which 
group therapy can be standardized and made more 
community-friendly.
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This section presents examples of  treatment approaches 
and components that have an evidence base supporting 
their use. Each approach is designed to address certain 
aspects of  drug addiction and its consequences for the 
individual, family, and society. Some of  the approaches 
are intended to supplement or enhance existing treatment 
programs, and others are fairly comprehensive in and  
of  themselves. 
The following section is broken down into 
Pharmacotherapies, Behavioral Therapies, and  
Behavioral Therapies Primarily for Adolescents.  
They are further subdivided according to particular 
substance use disorders. This list is not exhaustive,  
and new treatments are continually under development.
Pharmacotherapies
Opioid Addiction
Methadone
Methadone is a long-acting synthetic opioid agonist 
medication that can prevent withdrawal symptoms and 
reduce craving in opioid-addicted individuals. It can also 
block the effects of  illicit opioids. It has a long history 
of  use in treatment of  opioid dependence in adults and 
is taken orally. Methadone maintenance treatment is 
available in all but three States through specially licensed 
opioid treatment programs or methadone maintenance 
programs. 
Combined with behavioral treatment
Research has shown that methadone maintenance is 
more effective when it includes individual and/or group 
counseling, with even better outcomes when patients 
are provided with, or referred to, other needed medical/
psychiatric, psychological, and social services (e.g., 
employment or family services).
Evidence-Based 
Approaches to Drug 
Addiction Treatment
Each approach to drug treatment is 
designed to address certain aspects of  
drug addiction and its consequences 
for the individual, family, and society.
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*]XZMVWZXPQVM\ZMI\UMV\NWZLM\W`QÅKI\QWVIVLWZ
UIQV\MVIVKMKIVJMXZW^QLMLQVWNÅKMJI[ML[M\\QVO[Ja
Y]ITQÅMLXPa[QKQIV[_PWPI^MZMKMQ^MLI_IQ^MZNZWU\PM
Drug Enforcement Administration (DEA), allowing them 
\WXZM[KZQJMQ\<PMI^IQTIJQTQ\aWN WNÅKMJI[ML\ZMI\UMV\
for opioid addiction is a cost-effective approach that 
increases the reach of  treatment and the options available 
to patients.
Further Reading: 
Fiellin, D.A.; Pantalon, M.V.; Chawarski, M.C.; Moore, 
B.A.; Sullivan, L.E.; O’Connor, P.G.; and Schottenfeld, 
R.S. Counseling plus buprenorphine/naloxone 
maintenance therapy for opioid dependence. The New 
England Journal of Medicine 355(4):365–374, 2006. 
Fudala P.J.; Bridge, T.P.; Herbert, S.; Williford, W.O.; 
Chiang, C.N.; Jones, K.; Collins, J.; Raisch, D.; 
Casadonte, P.; Goldsmith, R.J.; Ling, W.; Malkerneker, 
U.; McNicholas, L.; Renner, J.; Stine, S.; and Tusel, D. 
for the Buprenorphine/Naloxone Collaborative Study 
/ZW]X7NÅKMJI[ML\ZMI\UMV\WN WXQI\MILLQK\QWV
with a sublingual-tablet formulation of  buprenorphine 
and naloxone. The New England Journal of Medicine 
349(10):949–958, 2003. 
Kosten, T.R.; and Fiellin, D.A. U.S. National 
Buprenorphine Implementation Program: Buprenorphine 
NWZWNÅKMJI[MLXZIK\QKM"+WV[MV[][KWVNMZMVKMW^MZ^QM_
The American Journal on Addictions 13(Suppl. 1):S1–S7, 
2004. 
5K+IVKM3I\b-.7NÅKMJI[MLJ]XZMVWZXPQVM
treatment for opioid-dependent patients. Harvard Review 
of Psychiatry 12(6):321–338, 2004. 
Further Reading:
Dole, V.P.; Nyswander, M.; and Kreek, M.J. Narcotic 
blockade. Archives of Internal Medicine 118:304–309, 
1966. 
McLellan, A.T.; Arndt, I.O.; Metzger, D.; Woody, G.E.; 
and O’Brien, C.P. The effects of  psychosocial services in 
substance abuse treatment. The Journal of the American 
Medical Association 269(15):1953–1959, 1993. 
<PM:WKSMNMTTMZ=VQ^MZ[Q\a<PMÅZ[\XPIZUIKWTWOQKIT
treatment for narcotic addiction: Methadone 
maintenance. The Rockefeller University Hospital 
Centennial, 2010. Available at centennial.rucares.org/index.
php?page=Methadone_Maintenance.
Woody, G.E.; Luborsky, L.; McClellan, A.T.; O’Brien, 
C.P.; Beck, A.T.; Blaine, J.; Herman, I.; and Hole, A. 
Psychotherapy for opiate addicts: Does it help? Archives of 
General Psychiatry 40:639–645, 1983.
Buprenorphine
Buprenorphine is a synthetic opioid medication that 
acts as a partial agonist at opioid receptors—it does not 
produce the euphoria and sedation caused by heroin or 
other opioids but is able to reduce or eliminate withdrawal 
symptoms associated with opioid dependence and carries 
a low risk of  overdose. 
Buprenorphine is currently available in two formulations 
that are taken sublingually: (1) a pure form of  the drug 
and (2) a more commonly prescribed formulation called 
Suboxone, which combines buprenorphine with the drug 
naloxone, an antagonist (or blocker) at opioid receptors. 
Naloxone has no effect when Suboxone is taken as 
prescribed, but if  an addicted individual attempts to inject 
Suboxone, the naloxone will produce severe withdrawal 
symptoms. Thus, this formulation lessens the likelihood 
that the drug will be abused or diverted to others. 
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or parolees. Recently, a long-acting injectable version of  
naltrexone, called Vivitrol, was approved to treat opioid 
addiction. Because it only needs to be delivered once a 
month, this version of  the drug can facilitate compliance 
and offers an alternative for those who do not wish to be 
placed on agonist/partial agonist medications.
Further Reading:
Cornish, J.W.; Metzger, D.; Woody, G.E.; Wilson, D.; 
McClellan, A.T.; and Vandergrift, B. Naltrexone 
pharmacotherapy for opioid dependent federal 
probationers. Journal of Substance Abuse Treatment 
14(6):529–534, 1997.
Gastfriend, D.R. Intramuscular extended-release 
naltrexone: current evidence. Annals of the New York 
Academy of Sciences 1216:144–166, 2011.
Krupitsky, E.; Illerperuma, A.; Gastfriend, D.R.; and 
;QT^MZUIV*4-NÅKIKaIVL[INM\aWN M`\MVLMLZMTMI[M
injectable naltrexone (XR-NTX) for the treatment of  
opioid dependence. Paper presented at the 2010 annual 
meeting of  the American Psychiatric Association, New 
Orleans, LA.
Tobacco Addiction
Nicotine Replacement Therapy (NRT)
A variety of  formulations of  nicotine replacement 
therapies (NRTs) now exist, including the transdermal 
nicotine patch, nicotine spray, nicotine gum, and nicotine 
lozenges. Because nicotine is the main addictive ingredient 
in tobacco, the rationale for NRT is that stable low levels 
of  nicotine will prevent withdrawal symptoms—which 
often drive continued tobacco use—and help keep people 
motivated to quit. Research shows that combining the 
patch with another replacement therapy is more effective 
than a single therapy alone.
Treatment, not Substitution
Because methadone and buprenorphine are themselves 
opioids, some people view these treatments for opioid 
dependence as just substitutions of  one addictive drug 
for another (see Question 19 above). But taking these 
medications as prescribed allows patients to hold jobs, 
avoid street crime and violence, and reduce their exposure 
to HIV by stopping or decreasing injection drug use and 
drug-related high-risk sexual behavior. Patients stabilized 
on these medications can also engage more readily in 
counseling and other behavioral interventions essential  
to recovery. 
Naltrexone
Naltrexone is a synthetic opioid antagonist—it blocks 
opioids from binding to their receptors and thereby 
prevents their euphoric and other effects. It has been 
used for many years to reverse opioid overdose and is also 
approved for treating opioid addiction. The theory behind 
this treatment is that the repeated absence of  the desired 
effects and the perceived futility of  abusing opioids will 
gradually diminish craving and addiction. Naltrexone 
Q\[MTN PI[VW[]JRMK\Q^MMNNMK\[NWTTW_QVOLM\W`QÅKI\QWV\PI\
is, a person does not perceive any particular drug effect), it 
has no potential for abuse, and it is not addictive. 
Naltrexone as a treatment for opioid addiction is usually 
prescribed in outpatient medical settings, although the 
treatment should begin afterUMLQKITLM\W`QÅKI\QWV
in a residential setting in order to prevent withdrawal 
symptoms. 
Naltrexone must be taken orally—either daily or three 
times a week—but noncompliance with treatment is a 
common problem. Many experienced clinicians have 
found naltrexone best suited for highly motivated, recently 
LM\W`QÅMLXI\QMV\[_PWLM[QZM\W\ITIJ[\QVMVKMJMKI][M
of  external circumstances—for instance, professionals 
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treatment, social, and work settings. Combined treatment is 
urged because behavioral and pharmacological treatments 
are thought to operate by different yet complementary 
mechanisms that can have additive effects. 
Further Reading:
Alterman, A.I.; Gariti, P.; and Mulvaney, F. Short- and 
long-term smoking cessation for three levels of  intensity 
of  behavioral treatment. Psychology of Addictive Behaviors 
15:261–264, 2001. 
0ITT;5#0]UÆMM\/4#5]}Wb:.#:M][>1#
Prochaska, J.J.; and Robbins, J.A. Using extended cognitive 
behavioral treatment and medication to treat dependent 
smokers. American Journal of Public Health 101:2349–
2356, 2011.
Jorenby, D.E.; Hays, J.T.; Rigotti, N.A.; Azoulay, S.; 
Watsky, E.J.; Williams, K.E.; Billing, C.B.; Gong, J.; and 
:MM^M[3:>IZMVQKTQVM8PI[M;\]La/ZW]X-NÅKIKa
of  varenicline, an Ơơ nicotinic acetylcholine receptor 
partial agonist vs. placebo or sustained-release bupropion 
for smoking cessation: A randomized controlled trial. The 
Journal of the American Medical Association 296(1):56–63, 
2006. 
King, D.P.; Paciqa, S.; Pickering, E.; Benowitz, N.L.; 
Bierut, L.J.; Conti, D.V.; Kaprio, J.; Lerman, C.; and Park, 
P.W. Smoking cessation pharmacogenetics: Analysis of  
varenicline and bupropion in placebo-controlled clinical 
trials. Neuropsychopharmacology 37:641–650, 2012.
Raupach, T.; and van Schayck, C.P. Pharmacotherapy for 
smoking cessation: Current advances and research topics. 
CNS Drugs 25:371–382, 2011.
Shah, S.D.; Wilken, L.A.; Winkler, S.R.; and Lin, S.J. 
Systematic review and meta-analysis of  combination 
therapy for smoking cessation. Journal of the American 
Pharmaceutical Association 48(5):659–665, 2008.
Bupropion (Zyban®)
Bupropion was originally marketed as an antidepressant 
(Wellbutrin). It produces mild stimulant effects by 
blocking the reuptake of  certain neurotransmitters, 
especially norepinephrine and dopamine. A serendipitous 
observation among depressed patients was that the 
medication was also effective in suppressing tobacco 
craving, helping them quit smoking without also gaining 
weight. Although bupropion’s exact mechanisms of  action 
in facilitating smoking cessation are unclear, it has FDA 
approval as a smoking cessation treatment.
Varenicline (Chantix®)
Varenicline is the most recently FDA-approved medication 
for smoking cessation. It acts on a subset of  nicotinic 
receptors in the brain thought to be involved in the 
rewarding effects of  nicotine. Varenicline acts as a partial 
agonist/antagonist at these receptors—this means that it 
UQTLTa[\QU]TI\M[\PMVQKW\QVMZMKMX\WZJ]\VW\[]NÅKQMV\Ta
to trigger the release of  dopamine, which is important 
for the rewarding effects of  nicotine. As an antagonist, 
varenicline also blocks the ability of  nicotine to activate 
dopamine, interfering with the reinforcing effects of  
smoking, thereby reducing cravings and supporting 
abstinence from smoking.
Combined With Behavioral Treatment
Each of  the above pharmacotherapies is recommended 
for use in combination with behavioral interventions, 
including group and individual therapies, as well as 
telephone quitlines. Behavioral approaches complement 
most tobacco addiction treatment programs. They can 
amplify the effects of  medications by teaching people 
how to manage stress, recognize and avoid high-risk 
situations for smoking relapse, and develop alternative 
coping strategies (e.g., cigarette refusal skills, assertiveness, 
and time management skills) that they can practice in 
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is generally poor. However, among patients who are 
PQOPTaUW\Q^I\MLLQ[]TÅZIUKIVJMMNNMK\Q^MIVL[WUM
patients use it episodically for high-risk situations, such as 
social occasions where alcohol is present. It can also be 
administered in a monitored fashion, such as in a clinic or 
JaI[XW][MQUXZW^QVOQ\[MNÅKIKa
Topiramate
Topiramate is thought to work by increasing inhibitory 
(GABA) neurotransmission and reducing stimulatory 
(glutamate) neurotransmission, although its precise 
mechanism of  action is not known. Although topiramate 
has not yet received FDA approval for treating alcohol 
addiction, it is sometimes used off-label for this purpose. 
<WXQZIUI\MPI[JMMV[PW_VQV[\]LQM[\W[QOVQÅKIV\Ta
improve multiple drinking outcomes, compared with a 
placebo. 
Combined With Behavioral Treatment
While a number of  behavioral treatments have been 
shown to be effective in the treatment of  alcohol 
addiction, it does not appear that an additive effect exists 
between behavioral treatments and pharmacotherapy. 
Studies have shown that just getting help is one of  the 
most important factors in treating alcohol addiction; the 
precise type of  treatment received is not as important. 
Further Reading: 
Anton, R.F.; O’Malley, S.S.; Ciraulo, D.A.; Cisler, R.A.; 
Couper, D.; Donovan, D.M.; Gastfriend, D.R.; Hosking, 
J.D.; Johnson, B.A.; LoCastro, J.S.; Longabaugh, R.; 
Mason, B.J.; Mattson, M.E.; Miller, W.R.; Pettinati, H.M.; 
Randall, C.L.; Swift, R.; Weiss, R.D.; Williams, L.D.; 
and Zweben, A., for the COMBINE Study Research 
Group. Combined pharmacotherapies and behavioral 
interventions for alcohol dependence: The COMBINE 
study: A randomized controlled trial. The Journal of the 
American Medical Association 295(17):2003–2017, 2006. 
Smith, S.S; McCarthy, D.E.; Japuntich S.J.; Christiansen, 
B.; Piper, M.E.; Jorenby, D.E.; Fraser, D.L.; Fiore, M.C.; 
Baker, T.B.; and Jackson, T.C. Comparative effectiveness 
of  5 smoking cessation pharmacotherapies in primary 
care clinics. Archives of Internal Medicine 169:2148–2155, 
2009.
Stitzer, M. Combined behavioral and pharmacological 
treatments for smoking cessation. Nicotine & Tobacco 
Research 1:S181–S187, 1999.
Alcohol Addiction
Naltrexone
Naltrexone blocks opioid receptors that are involved in 
the rewarding effects of  drinking and the craving for 
alcohol. It has been shown to reduce relapse to problem 
drinking in some patients. An extended release version, 
Vivitrol—administered once a month by injection—is 
also FDA-approved for treating alcoholism, and may offer 
JMVMÅ\[ZMOIZLQVOKWUXTQIVKM
Acamprosate
Acamprosate (Campral®) acts on the gamma-aminobutyric 
acid (GABA) and glutamate neurotransmitter systems and 
is thought to reduce symptoms of  protracted withdrawal, 
such as insomnia, anxiety, restlessness, and dysphoria. 
Acamprosate has been shown to help dependent drinkers 
maintain abstinence for several weeks to months, and it 
may be more effective in patients with severe dependence. 
Disulfiram
,Q[]TÅZIU)V\IJ][M®) interferes with degradation of  
alcohol, resulting in the accumulation of  acetaldehyde, 
which, in turn, produces a very unpleasant reaction 
\PI\QVKT]LM[Æ][PQVOVI][MIIVLXITXQ\I\QWV[QN I
person drinks alcohol. The utility and effectiveness of  
LQ[]TÅZIUIZMKWV[QLMZMLTQUQ\MLJMKI][MKWUXTQIVKM
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include exploring the positive and negative consequences 
of  continued drug use, self-monitoring to recognize 
cravings early and identify situations that might put one 
at risk for use, and developing strategies for coping with 
cravings and avoiding those high-risk situations. 
Research indicates that the skills individuals learn 
through cognitive-behavioral approaches remain after the 
completion of  treatment. Current research focuses on how 
to produce even more powerful effects by combining CBT 
with medications for drug abuse and with other types of  
behavioral therapies. A computer-based CBT system has 
also been developed and has been shown to be effective 
in helping reduce drug use following standard drug abuse 
treatment.
Further Reading:
Carroll, K.M., Easton, C.J.; Nich, C.; Hunkele, K.A.; 
Neavins, T.M.; Sinha, R.; Ford, H.L.; Vitolo, S.A; 
Doebrick, C.A.; and Rounsaville, B.J. The use of  
contingency management and motivational/skills-building 
therapy to treat young adults with marijuana dependence. 
Journal of Consulting and Clinical Psychology 74(5):955–
966, 2006. 
Carroll, K.M.; and Onken, L.S. Behavioral therapies 
for drug abuse. The American Journal of Psychiatry 
168(8):1452–1460, 2005. 
Carroll, K.M.; Sholomskas, D.; Syracuse, G.; Ball, S.A.; 
Nuro, K.; and Fenton, L.R. We don’t train in vain: A 
dissemination trial of  three strategies of  training clinicians 
in cognitive-behavioral therapy. Journal of Consulting and 
Clinical Psychology 73(1):106–115, 2005. 
Carroll, K.; Fenton, L.R.; Ball, S.A.; Nich, C.; Frankforter, 
<4#;PQ2#IVL:W]V[I^QTTM*2-NÅKIKaWN LQ[]TÅZIU
and cognitive behavior therapy in cocaine-dependent 
outpatients: A randomized placebo-controlled trial. 
Archives of General Psychiatry 61(3):264–272, 2004. 
National Institute on Alcohol Abuse and Alcoholism. 
Helping Patients Who Drink Too Much: A Clinician’s 
Guide, Updated 2005 Edition. Bethesda, MD: NIAAA, 
updated 2005. Available at pubs.niaaa.nih.gov/
publications/Practitioner/CliniciansGuide2005/clinicians_
guide.htm
Behavioral Therapies
Behavioral approaches help engage people in drug 
abuse treatment, provide incentives for them to remain 
abstinent, modify their attitudes and behaviors related 
to drug abuse, and increase their life skills to handle 
stressful circumstances and environmental cues that 
may trigger intense craving for drugs and prompt 
another cycle of  compulsive abuse. Below are a 
number of  behavioral therapies shown to be effective 
in addressing substance abuse (effectiveness with 
particular drugs of  abuse is denoted in parentheses).
Cognitive-Behavioral Therapy  
(Alcohol, Marijuana, Cocaine, 
Methamphetamine, Nicotine)
Cognitive-Behavioral Therapy (CBT) was developed 
as a method to prevent relapse when treating problem 
drinking, and later it was adapted for cocaine-addicted 
individuals. Cognitive-behavioral strategies are based 
on the theory that in the development of  maladaptive 
behavioral patterns like substance abuse, learning 
processes play a critical role. Individuals in CBT learn to 
identify and correct problematic behaviors by applying 
a range of  different skills that can be used to stop drug 
abuse and to address a range of  other problems that often 
co-occur with it. 
A central element of  CBT is anticipating likely problems 
and enhancing patients’ self-control by helping them 
LM^MTWXMNNMK\Q^MKWXQVO[\ZI\MOQM[;XMKQÅK\MKPVQY]M[
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more times weekly), participants supplying drug-negative 
urine or breath tests draw from a bowl for the chance to 
win a prize worth between $1 and $100. Participants may 
also receive draws for attending counseling sessions and 
completing weekly goal-related activities. The number 
of  draws starts at one and increases with consecutive 
negative drug tests and/or counseling sessions attended 
but resets to one with any drug-positive sample or 
unexcused absence. The practitioner community has 
raised concerns that this intervention could promote 
gambling—as it contains an element of  chance—and that 
pathological gambling and substance use disorders can be 
comorbid. However, studies examining this concern found 
that Prize Incentives CM did not promote gambling 
behavior.
Further Reading:
Budney, A.J.; Moore, B.A.; Rocha, H.L.; and Higgins, S.T. 
Clinical trial of  abstinence-based vouchers and cognitive-
behavioral therapy for cannabis dependence. Journal of 
Consulting and Clinical Psychology 74(2):307–316, 2006. 
Budney, A.J.; Roffman, R.; Stephens, R.S.; and Walker, 
D. Marijuana dependence and its treatment. Addiction 
Science & Clinical Practice 4(1):4–16, 2007. 
Elkashef, A.; Vocci, F.; Huestis, M.; Haney, M.; 
Budney, A.; Gruber, A.; and el-Guebaly, N. Marijuana 
neurobiology and treatment. Substance Abuse 29(3):17–29, 
2008. 
Peirce, J.M.; Petry, N.M.; Stitzer, M.L.; Blaine, J.; Kellogg, 
;#;I\\MZÅMTL.#;KP_IZ\b5#3ZI[VIV[Sa2#8MVKMZ
E.; Silva-Vazquez, L.; Kirby, K.C.; Royer-Malvestuto, C.; 
Cohen, A.; Copersino, M.L.; Kolodner, K.; and Li, R. 
Effects of  lower-cost incentives on stimulant abstinence 
in methadone maintenance treatment: A National Drug 
Abuse Treatment Clinical Trials Network study. Archives 
of General Psychiatry 63(2):201–208, 2006. 
Carroll, K.M.; Ball, S.A.; Martino, S.; Nich, C.; Babuscio, 
T.A.; Nuro, K.F.; Gordon, M.A.; Portnoy, G.A.; and 
Rounsaville, B.J. Computer-assisted delivery of  cognitive-
behavioral therapy for addiction: a randomized trial 
of  CBT4CBT. The American Journal of Psychiatry 
165(7):881–888, 2008.
Contingency Management Interventions/
Motivational Incentives  
(Alcohol, Stimulants, Opioids,  
Marijuana, Nicotine)
Research has demonstrated the effectiveness of  treatment 
approaches using contingency management (CM) 
principles, which involve giving patients tangible rewards 
to reinforce positive behaviors such as abstinence. 
Studies conducted in both methadone programs and 
psychosocial counseling treatment programs demonstrate 
that incentive-based interventions are highly effective in 
increasing treatment retention and promoting abstinence 
from drugs. 
Voucher-Based Reinforcement (VBR) augments other 
community-based treatments for adults who primarily 
abuse opioids (especially heroin) or stimulants (especially 
cocaine) or both. In VBR, the patient receives a voucher 
for every drug-free urine sample provided. The voucher 
has monetary value that can be exchanged for food items, 
movie passes, or other goods or services that are consistent 
with a drug-free lifestyle. The voucher values are low at 
ÅZ[\J]\QVKZMI[MI[\PMV]UJMZWN KWV[MK]\Q^MLZ]ONZMM
urine samples increases; positive urine samples reset the 
value of  the vouchers to the initial low value. VBR has 
been shown to be effective in promoting abstinence from 
opioids and cocaine in patients undergoing methadone 
LM\W`QÅKI\QWV
Prize Incentives CM applies similar principles as VBR 
but uses chances to win cash prizes instead of  vouchers. 
Over the course of  the program (at least 3 months, one or 
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C.; Hamilton, J.; Booth, R.E.; Macdonald, M.; Liebert, 
M.; Rader, L.; Burns, R; DiMaria, J.; Copersino, M.; 
Stabile, P.Q.; Kolodner, K.; and Li, R. Effect of  prize-
based incentives on outcomes in stimulant abusers in 
outpatient psychosocial treatment programs: A National 
Drug Abuse Treatment Clinical Trials Network study. 
Archives of General Psychiatry 62(10):1148–1156, 2005. 
Petry, N.M.; Kolodner, K.B.; Li, R.; Peirce, J.M.; Roll, 
J.M.; Stitzer, M.L.; and Hamilton, J.A. Prize-based 
contingency management does not increase gambling. 
Drug and Alcohol Dependence 83(3):269–273, 2006. 
Prendergast, M.; Podus, D.; Finney, J.; Greenwell, L.; 
and Roll, J. Contingency management for treatment 
of  substance use disorders: A meta-analysis. Addiction 
101(11):1546–1560, 2006. 
Roll, J.M.; Petry, N.M.; Stitzer, M.L.; Brecht, M.L.; Peirce, 
J.M.; McCann, M.J.; Blaine, J.; MacDonald, M.; DiMaria, 
J.; Lucero, L.; and Kellogg, S. Contingency management 
for the treatment of  methamphetamine use disorders. The 
American Journal of Psychiatry 163(11):1993–1999, 2006.
Community Reinforcement Approach Plus 
Vouchers (Alcohol, Cocaine, Opioids)
Community Reinforcement Approach (CRA) Plus 
Vouchers is an intensive 24-week outpatient therapy for 
treating people addicted to cocaine and alcohol. It uses 
a range of  recreational, familial, social, and vocational 
reinforcers, along with material incentives, to make a non-
drug-using lifestyle more rewarding than substance use. 
The treatment goals are twofold:
 To maintain abstinence long enough for patients to 
learn new life skills to help sustain it; and
 To reduce alcohol consumption for patients whose 
drinking is associated with cocaine use
Patients attend one or two individual counseling sessions 
each week, where they focus on improving family relations, 
learn a variety of  skills to minimize drug use, receive 
vocational counseling, and develop new recreational 
activities and social networks. Those who also abuse 
ITKWPWTZMKMQ^MKTQVQKUWVQ\WZMLLQ[]TÅZIU)V\IJ][M
therapy. Patients submit urine samples two or three times 
each week and receive vouchers for cocaine-negative 
samples. As in VBR, the value of  the vouchers increases 
with consecutive clean samples, and the vouchers may be 
exchanged for retail goods that are consistent with a drug-
free lifestyle. Studies in both urban and rural areas have 
found that this approach facilitates patients’ engagement 
in treatment and successfully aids them in gaining 
substantial periods of  cocaine abstinence. 
A computer-based version of  CRA Plus Vouchers called 
the Therapeutic Education System (TES) was found to be 
nearly as effective as treatment administered by a therapist 
in promoting abstinence from opioids and cocaine among 
opioid-dependent individuals in outpatient treatment. A 
version of  CRA for adolescents addresses problem-solving, 
coping, and communication skills and encourages active 
participation in positive social and recreational activities. 
Further Reading: 
Brooks, A.C.; Ryder, D.; Carise, D.; and Kirby, K.C. 
Feasibility and effectiveness of  computer-based therapy 
in community treatment. Journal of Substance Abuse 
Treatment 39(3):227–235, 2010.
Higgins, S.T.; Sigmon, S.C.; Wong, C.J.; Heil, S.H.; 
Badger, G.J.; Donham, R.; Dantona, R.L.; and Anthony, S. 
Community reinforcement therapy for cocaine-dependent 
outpatients. Archives of General Psychiatry 60(10):1043–
1052, 2003. 
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Sustained cocaine abstinence in methadone maintenance 
patients through voucher-based reinforcement therapy. 
Archives of General Psychiatry 53(5):409–415, 1996. 
Smith, J.E.; Meyers, R.J.; and Delaney, H.D. The 
community reinforcement approach with homeless 
alcohol-dependent individuals. Journal of Consulting and 
Clinical Psychology 66(3):541–548, 1998. 
Stahler, G.J.; Shipley, T.E.; Kirby, K.C.; Godboldte, C.; 
Kerwin, M.E; Shandler, I.; and Simons, L. Development 
and initial demonstration of  a community-based 
intervention for homeless, cocaine-using, African-
American women. Journal of Substance Abuse Treatment 
28(2):171–179, 2005.
Motivational Enhancement Therapy 
(Alcohol, Marijuana, Nicotine)
Motivational Enhancement Therapy (MET) is a 
counseling approach that helps individuals resolve their 
ambivalence about engaging in treatment and stopping 
their drug use. This approach aims to evoke rapid and 
internally motivated change, rather than guide the 
patient stepwise through the recovery process. This 
therapy consists of  an initial assessment battery session, 
followed by two to four individual treatment sessions with 
I\PMZIXQ[\1V\PMÅZ[\\ZMI\UMV\[M[[QWV\PM\PMZIXQ[\
provides feedback to the initial assessment, stimulating 
discussion about personal substance use and eliciting 
self-motivational statements. Motivational interviewing 
principles are used to strengthen motivation and build 
a plan for change. Coping strategies for high-risk 
situations are suggested and discussed with the patient. 
In subsequent sessions, the therapist monitors change, 
reviews cessation strategies being used, and continues to 
encourage commitment to change or sustained abstinence. 
8I\QMV\[[WUM\QUM[IZMMVKW]ZIOML\WJZQVOI[QOVQÅKIV\
other to sessions. 
Research on MET suggests that its effects depend on 
the type of  drug used by participants and on the goal 
of  the intervention. This approach has been used 
successfully with people addicted to alcohol to both 
improve their engagement in treatment and reduce their 
problem drinking. MET has also been used successfully 
with marijuana-dependent adults when combined 
with cognitive-behavioral therapy, constituting a more 
comprehensive treatment approach. The results of  MET 
are mixed for people abusing other drugs (e.g., heroin, 
cocaine, nicotine) and for adolescents who tend to use 
multiple drugs. In general, MET seems to be more 
effective for engaging drug abusers in treatment than for 
producing changes in drug use.
Further Reading:
Baker, A.; Lewin, T.; Reichler, H.; Clancy, R.; Carr, V.; 
Garrett, R.; Sly, K.; Devir, H.; and Terry, M. Evaluation 
of  a motivational interview for substance use with 
psychiatric in-patient services. Addiction 97(10):1329–1337, 
2002. 
Haug, N.A.; Svikis, D.S.; and Diclemente, C. Motivational 
enhancement therapy for nicotine dependence in 
methadone-maintained pregnant women. Psychology of 
Addictive Behaviors 18(3):289–292, 2004. 
Marijuana Treatment Project Research Group. Brief  
treatments for cannabis dependence: Findings from a 
randomized multisite trial. Journal of Consulting and 
Clinical Psychology 72(3):455–466, 2004. 
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Miller, W.R.; Yahne, C.E.; and Tonigan, J.S. Motivational 
interviewing in drug abuse services: A randomized trial. 
Journal of Consulting and Clinical Psychology 71(4):754–
763, 2003. 
Stotts, A.L.; Diclemente, C.C.; and Dolan-Mullen, P. One-
to-one: A motivational intervention for resistant pregnant 
smokers. Addictive Behaviors 27(2):275–292, 2002.
The Matrix Model (Stimulants)
The Matrix Model provides a framework for engaging 
stimulant (e.g., methamphetamine and cocaine) abusers in 
treatment and helping them achieve abstinence. Patients 
learn about issues critical to addiction and relapse, receive 
direction and support from a trained therapist, and 
become familiar with self-help programs. Patients are 
monitored for drug use through urine testing. 
The therapist functions simultaneously as teacher and 
coach, fostering a positive, encouraging relationship 
with the patient and using that relationship to reinforce 
positive behavior change. The interaction between the 
therapist and the patient is authentic and direct but not 
confrontational or parental. Therapists are trained to 
conduct treatment sessions in a way that promotes the 
patient’s self-esteem, dignity, and self-worth. A positive 
relationship between patient and therapist is critical to 
patient retention. 
Treatment materials draw heavily on other tested 
treatment approaches and, thus, include elements of  
relapse prevention, family and group therapies, drug 
education, and self-help participation. Detailed treatment 
manuals contain worksheets for individual sessions; 
other components include family education groups, 
early recovery skills groups, relapse prevention groups, 
combined sessions, urine tests, 12-step programs, relapse 
analysis, and social support groups. 
A number of  studies have demonstrated that participants 
treated using the Matrix Model show statistically 
[QOVQÅKIV\ZML]K\QWV[QVLZ]OIVLITKWPWT][M
improvements in psychological indicators, and reduced 
risky sexual behaviors associated with HIV transmission.
Further Reading:
Huber, A.; Ling, W.; Shoptaw, S.; Gulati, V.; Brethen, 
P.; and Rawson, R. Integrating treatments for 
methamphetamine abuse: A psychosocial perspective. 
Journal of Addictive Diseases 16(4):41–50, 1997. 
Rawson, R.; Shoptaw, S.J.; Obert, J.L.; McCann, M.J.; 
Hasson, A.L.; Marinelli-Casey, P.J.; Brethen, P.R.; and 
Ling, W. An intensive outpatient approach for cocaine 
abuse: The Matrix model. Journal of Substance Abuse 
Treatment 12(2):117–127, 1995. 
Rawson, R.A.; Huber, A.; McCann, M.; Shoptaw, S.; 
Farabee, D.; Reiber, C.; and Ling, W. A comparison 
of  contingency management and cognitive-behavioral 
approaches during methadone maintenance treatment 
for cocaine dependence. Archives of General Psychiatry 
59(9):817–824, 2002.
12-Step Facilitation Therapy  
(Alcohol, Stimulants, Opioids)
Twelve-step facilitation therapy is an active engagement 
strategy designed to increase the likelihood of  a substance 
IJ][MZJMKWUQVOINÅTQI\ML_Q\PIVLIK\Q^MTaQV^WT^MLQV
12-step self-help groups, thereby promoting abstinence. 
Three key ideas predominate: (1) acceptance, which 
includes the realization that drug addiction is a chronic, 
progressive disease over which one has no control, that 
life has become unmanageable because of  drugs, that 
_QTTXW_MZITWVMQ[QV[]NÅKQMV\\WW^MZKWUM\PMXZWJTMU
and that abstinence is the only alternative; (2) surrender, 
which involves giving oneself  over to a higher power, 
accepting the fellowship and support structure of  other 
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recovering addicted individuals, and following the recovery 
activities laid out by the 12-step program; and (3) active 
involvement in 12-step meetings and related activities. 
?PQTM\PMMNÅKIKaWN [\MXXZWOZIU[IVL[\MX
facilitation) in treating alcohol dependence has been 
established, the research on its usefulness for other  
forms of  substance abuse is more preliminary, but the 
treatment appears promising for helping drug abusers 
sustain recovery.
Further Reading:
Carroll, K.M.; Nich, C.; Ball, S.A.; McCance, E.; 
Frankforter, T.L.; and Rounsaville, B.J. One-year follow-up 
WN LQ[]TÅZIUIVLX[aKPW\PMZIXaNWZKWKIQVMITKWPWT][MZ["
Sustained effects of  treatment. Addiction 95(9):1335–1349, 
2000. 
,WVW^IV,5#IVL?MTT[-)¹<_MISQVO[\MXº"<PM
potential role of  12-Step self-help group involvement in 
methamphetamine recovery. Addiction 102(Suppl. 1):121–
129, 2007. 
Project MATCH Research Group. Matching alcoholism 
treatments to client heterogeneity: Project MATCH 
posttreatment drinking outcomes. Journal of Studies on 
Alcohol 58(1)7–29, 1997.
Family Behavior Therapy
Family Behavior Therapy (FBT), which has demonstrated 
positive results in both adults and adolescents, is aimed 
at addressing not only substance use problems but other 
co-occurring problems as well, such as conduct disorders, 
KPQTLUQ[\ZMI\UMV\LMXZM[[QWVNIUQTaKWVÆQK\IVL
unemployment. FBT combines behavioral contracting 
with contingency management. 
.*<QV^WT^M[\PMXI\QMV\ITWVO_Q\PI\TMI[\WVM[QOVQÅKIV\
other such as a cohabiting partner or a parent (in the 
case of  adolescents). Therapists seek to engage families in 
applying the behavioral strategies taught in sessions and 
in acquiring new skills to improve the home environment. 
Patients are encouraged to develop behavioral goals 
for preventing substance use and HIV infection, which 
are anchored to a contingency management system. 
Substance-abusing parents are prompted to set goals 
related to effective parenting behaviors. During each 
session, the behavioral goals are reviewed, with rewards 
XZW^QLMLJa[QOVQÅKIV\W\PMZ[_PMVOWIT[IZMIKKWUXTQ[PML
8I\QMV\[XIZ\QKQXI\MQV\ZMI\UMV\XTIVVQVOKPWW[QVO[XMKQÅK
interventions from a menu of  evidence-based treatment 
options. In a series of  comparisons involving adolescents 
with and without conduct disorder, FBT was found to be 
more effective than supportive counseling.
Further Reading:
Azrin, N.H.; Donohue, B.; Besalel, V.A.; Kogan, E.S.; 
and Acierno, R. Youth drug abuse treatment: a controlled 
outcome study. Journal of Child and Adolescent Substance 
Abuse 3:1–16, 1994.
Carroll, K.M.; and Onken, L.S. Behavioral therapies for 
drug abuse. American Journal of Psychiatry 168(8):1452–
1460, 2005. 
Donohue, B.; Azrin, N.; Allen, D.N.; Romero, V.; Hill, 
H.H.; Tracy, K.; Lapota, H.; Gorney, S.; Abdel-al, R.; 
Caldas, D.; Herdzik, K.; Bradshaw, K.; Valdez, R.; and 
Van Hasselt, V.B. Family Behavior Therapy for substance 
abuse: A review of  its intervention components and 
applicability. Behavior Modification, 33:495–519, 2009.
LaPota, H.B.; Donohue, B.; Warren, C. S.; and Allen, D.N. 
Integration of  a Healthy Living curriculum within Family 
Behavior Therapy: A clinical case example in a woman 
with a history of  domestic violence, child neglect, drug 
abuse, and obesity. Journal of Family Violence 26:227–234, 
2011. 
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Behavioral Therapies Primarily 
for Adolescents 
Drug-abusing and addicted adolescents have unique 
treatment needs. Research has shown that treatments 
designed for and tested in adult populations often need 
\WJMUWLQÅML\WJMMNNMK\Q^MQVILWTM[KMV\[.IUQTa
involvement is a particularly important component for 
interventions targeting youth. Below are examples of  
behavioral interventions that employ these principles and 
PI^M[PW_VMNÅKIKaNWZ\ZMI\QVOILLQK\QWVQVaW]\P
Multisystemic Therapy
Multisystemic Therapy (MST) addresses the factors 
associated with serious antisocial behavior in children and 
adolescents who abuse alcohol and other drugs. These 
factors include characteristics of  the child or adolescent 
(e.g., favorable attitudes toward drug use), the family (poor 
LQ[KQXTQVMNIUQTaKWVÆQK\XIZMV\ITLZ]OIJ][MXMMZ[
(positive attitudes toward drug use), school (dropout, poor 
performance), and neighborhood (criminal subculture). 
By participating in intensive treatment in natural 
environments (homes, schools, and neighborhood settings), 
most youths and families complete a full course of  
\ZMI\UMV\5;<[QOVQÅKIV\TaZML]KM[ILWTM[KMV\LZ]O][M
during treatment and for at least 6 months after treatment. 
Fewer incarcerations and out-of-home juvenile placements 
offset the cost of  providing this intensive service and 
maintaining the clinicians’ low caseloads. 
Further Reading: 
Henggeler, S.W.; Clingempeel, W.G.; Brondino, M.J.; and 
Pickrel, S.G. Four-year follow-up of  multisystemic therapy 
with substance-abusing and substance-dependent juvenile 
offenders. Journal of the American Academy of Child and 
Adolescent Psychiatry 41(7):868–874, 2002. 
Henggeler, S.W.; Rowland, M.D.; Randall, J.; Ward, 
D.M.; Pickrel, S.G.; Cunningham, P.B.; Miller, S.L.; 
Edwards, J.; Zealberg, J.J.; Hand, L.D.; and Santos, A.B. 
Home-based multisystemic therapy as an alternative to 
the hospitalization of  youths in psychiatric crisis: Clinical 
outcomes. Journal of the American Academy of Child and 
Adolescent Psychiatry 38(11):1331–1339, 1999. 
Henggeler, S.W.; Halliday-Boykins, C.A.; Cunningham, 
P.B.; Randall, J.; Shapiro, S.B.; and Chapman, J.E. 
Juvenile drug court: Enhancing outcomes by integrating 
evidence-based treatments. Journal of Consulting and 
Clinical Psychology 74(1):42–54, 2006. 
Henggeler, S.W.; Pickrel, S.G.; Brondino, M.J.; and 
Crouch, J.L. Eliminating (almost) treatment dropout of  
substance-abusing or dependent delinquents through 
home-based multisystemic therapy. The American Journal 
of Psychiatry 153(3):427–428, 1996. 
Huey, S.J.; Henggeler, S.W.; Brondino, M.J.; and 
Pickrel, S.G. Mechanisms of  change in multisystemic 
therapy: Reducing delinquent behavior through therapist 
adherence and improved family functioning. Journal of 
Consulting and Clinical Psychology 68(3):451–467, 2000. 
Multidimensional Family Therapy
Multidimensional Family Therapy (MDFT) for adolescents 
is an outpatient, family-based treatment for teenagers who 
abuse alcohol or other drugs. MDFT views adolescent 
LZ]O][MQV\MZU[WN IVM\_WZSWN QVÆ]MVKM[QVLQ^QL]IT
family, peer, community) and suggests that reducing 
unwanted behavior and increasing desirable behavior 
occur in multiple ways in different settings. Treatment 
includes individual and family sessions held in the clinic, 
in the home, or with family members at the family court, 
school, or other community locations. 
During individual sessions, the therapist and adolescent 
work on important developmental tasks, such as 
developing decision-making, negotiation, and problem-
solving skills. Teenagers acquire vocational skills and 
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skills in communicating their thoughts and feelings to 
deal better with life stressors. Parallel sessions are held 
with family members. Parents examine their particular 
XIZMV\QVO[\aTM[TMIZVQVO\WLQ[\QVO]Q[PQVÆ]MVKMNZWU
control and to have a positive and developmentally 
IXXZWXZQI\MQVÆ]MVKMWV\PMQZKPQTLZMV
Further Reading: 
Dennis, M.; Godley, S.H.; Diamond, G.; Tims, F.M.; 
Babor, T.; Donaldson, J.; Liddle, H.; Titus, J.C.; Kaminer, 
Y.; Webb, C.; Hamilton, N.; and Funk, R. The Cannabis 
AW]\P<ZMI\UMV\+A<;\]La"5IQVÅVLQVO[NZWU\_W
randomized clinical trials. Journal of Substance Abuse 
Treatment 27(3):197–213, 2004. 
Liddle, H.A.; Dakof, G.A.; Parker, K.; Diamond, 
G.S.; Barrett, K.; and Tejeda, M. Multidimensional 
family therapy for adolescent drug abuse: Results of  a 
randomized clinical trial. The American Journal of Drug 
and Alcohol Abuse 27(4):651–688, 2001. 
Liddle, H.A.; and Hogue, A. Multidimensional family 
therapy for adolescent substance abuse. In E.F. Wagner 
and H.B. Waldron (eds.), Innovations in Adolescent 
Substance Abuse Interventions. London: Pergamon/
Elsevier Science, pp. 227–261, 2001. 
Liddle, H.A.; Rowe, C.L.; Dakof, G.A.; Ungaro, R.A.; 
and Henderson, C.E. Early intervention for adolescent 
substance abuse: Pretreatment to posttreatment outcomes 
of  a randomized clinical trial comparing multidimensional 
family therapy and peer group treatment. Journal of 
Psychoactive Drugs 36(1):49–63, 2004. 
Schmidt, S.E.; Liddle, H.A.; and Dakof, G.A. Effects of  
multidimensional family therapy: Relationship of  changes 
in parenting practices to symptom reduction in adolescent 
substance abuse. Journal of Family Psychology 10(1):1–16, 
1996. 
Brief Strategic Family Therapy
Brief  Strategic Family Therapy (BSFT) targets family 
interactions that are thought to maintain or exacerbate 
adolescent drug abuse and other co-occurring problem 
behaviors. Such problem behaviors include conduct 
problems at home and at school, oppositional behavior, 
delinquency, associating with antisocial peers, aggressive 
and violent behavior, and risky sexual behavior. BSFT 
is based on a family systems approach to treatment, in 
which family members’ behaviors are assumed to be 
interdependent such that the symptoms of  one member 
(the drug-abusing adolescent, for example) are indicative, 
at least in part, of  what else is occurring in the family 
system. The role of  the BSFT counselor is to identify the 
patterns of  family interaction that are associated with the 
adolescent’s behavior problems and to assist in changing 
those problem-maintaining family patterns. BSFT is 
UMIV\\WJMIÆM`QJTMIXXZWIKP\PI\KIVJMILIX\ML\WI
broad range of  family situations in various settings (mental 
health clinics, drug abuse treatment programs, other 
social service settings, and families’ homes) and in various 
treatment modalities (as a primary outpatient intervention, 
in combination with residential or day treatment, and as 
an aftercare/continuing-care service following residential 
treatment). 
Further Reading: 
Coatsworth, J.D.; Santisteban, D.A.; McBride, C.K.; and 
Szapocznik, J. Brief  Strategic Family Therapy versus 
community control: Engagement, retention, and an 
exploration of  the moderating role of  adolescent severity. 
Family Process 40(3):313–332, 2001. 
3]Z\QVM[?5#5]ZZIa-2#IVL4IXMZZQMZM)-NÅKIKa
of  intervention for engaging youth and families into 
treatment and some variables that may contribute to 
differential effectiveness. Journal of Family Psychology 
10(1):35–44, 1996. 
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Santisteban, D.A.; Coatsworth, J.D.; Perez-Vidal, A.; 
Mitrani, V.; Jean-Gilles, M.; and Szapocznik, J. Brief  
Structural/Strategic Family Therapy with African-
American and Hispanic high-risk youth. Journal of 
Community Psychology 25(5):453–471, 1997. 
Santisteban, D.A.; Suarez-Morales, L.; Robbins, M.S.; 
and Szapocznik, J. Brief  strategic family therapy: Lessons 
TMIZVMLQVMNÅKIKaZM[MIZKPIVLKPITTMVOM[\WJTMVLQVO
research and practice. Family Process 45(2):259–271, 2006. 
Santisteban, D.A.; Szapocznik, J.; Perez-Vidal, A.; Mitrani, 
V.; Jean-Gilles, M.; and Szapocznik, J. Brief  Structural/
Strategic Family Therapy with African-American 
and Hispanic high-risk youth. Journal of Community 
Psychology 25(5):453–471, 1997.
Szapocznik, J.; Perez-Vidal, A.; Brickman, A.L.; Foote, 
F.H.; Santisteban, D.; Hervis, O.; and Kurtines, W.M. 
Engaging adolescent drug abusers and their families in 
treatment: A strategic structural systems approach. Journal 
of Consulting and Clinical Psychology 56(4):552–557, 
1988. 
Functional Family Therapy
Functional Family Therapy (FFT) is another treatment 
based on a family systems approach, in which an 
adolescent’s behavior problems are seen as being created 
or maintained by a family’s dysfunctional interaction 
patterns. FFT aims to reduce problem behaviors by 
QUXZW^QVOKWUU]VQKI\QWVXZWJTMU[WT^QVOKWVÆQK\
resolution, and parenting skills. The intervention always 
includes the adolescent and at least one family member 
in each session. Principal treatment tactics include (1) 
engaging families in the treatment process and enhancing 
their motivation for change and (2) bringing about 
changes in family members’ behavior using contingency 
management techniques, communication and problem-
solving, behavioral contracts, and other behavioral 
interventions.
Further Reading: 
Waldron, H.B.; Slesnick, N.; Brody, J.L.; Turner, C.W.; 
and Peterson, T.R. Treatment outcomes for adolescent 
substance abuse at 4- and 7-month assessments. Journal of 
Consulting and Clinical Psychology 69:802–813, 2001.
Waldron, H.B.; Turner, C. W.; and Ozechowski, T. J. 
8ZWÅTM[WN LZ]O][MJMPI^QWZKPIVOMNWZILWTM[KMV\[QV
treatment. Addictive Behaviors 30:1775–1796, 2005.
Adolescent Community Reinforcement 
Approach and Assertive Continuing Care
The Adolescent Community Reinforcement Approach 
(A-CRA) is another comprehensive substance abuse 
treatment intervention that involves the adolescent and 
his or her family. It seeks to support the individual’s 
recovery by increasing family, social, and educational/
vocational reinforcers. After assessing the adolescent’s 
needs and levels of  functioning, the therapist chooses from 
among 17 A-CRA procedures to address problem-solving, 
coping, and communication skills and to encourage active 
participation in positive social and recreational activities. 
A-CRA skills training involves role-playing and behavioral 
rehearsal.
Assertive Continuing Care (ACC) is a home-based 
continuing-care approach to preventing relapse. Weekly 
home visits take place over a 12- to 14-week period after 
an adolescent is discharged from residential, intensive 
outpatient, or regular outpatient treatment. Using positive 
and negative reinforcement to shape behaviors, along with 
training in problem-solving and communication skills, 
ACC combines A-CRA and assertive case management 
services (e.g., use of  a multidisciplinary team of  
professionals, round-the-clock coverage, assertive outreach) 
to help adolescents and their caregivers acquire the skills 
to engage in positive social activities. 
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Further Reading: 
Dennis, M.; Godley, S.H.; Diamond, G.; Tims, F.M.; 
Babor, T.; Donaldson, J.; Liddle, H.; Titus, J.C.; Kamier, 
Y.; Webb, C.; Hamilton, N.; and Funk R. The Cannabis 
AW]\P<ZMI\UMV\+A<;\]La"5IQVÅVLQVO[NZWU\_W
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27:197–213, 2004.
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\ZMI\UMV\IVLKWV\QV]QVOKIZM"5IQVÅVLQVO[NZWUI
randomized clinical trial. Drug and Alcohol Dependence 
Jul 1;110 (1-2):44–54, 2010.
Godley, M.D.; Godley, S.H.; Dennis, M.L.; Funk, R.; and 
Passetti, L.L. Preliminary outcomes from the assertive 
continuing care experiment for adolescents discharged 
from residential treatment. Journal of Substance Abuse 
Treatment 23:21–32, 2002.
6968 Resources
National Agencies
The National Institute on Drug Abuse (NIDA) leads 
\PM6I\QWVQV[KQMV\QÅKZM[MIZKPWV\PMPMIT\PI[XMK\[
of  drug abuse and addiction. It supports and conducts 
research across a broad range of  disciplines, including 
genetics, functional neuroimaging, social neuroscience, 
prevention, medication and behavioral therapies, 
and health services. It then disseminates the results 
WN \PI\ZM[MIZKP\W[QOVQÅKIV\TaQUXZW^MXZM^MV\QWV
and treatment and to inform policy as it relates to 
drug abuse and addiction. Additional information is 
available at drugabuse.gov or by calling 301-443-1124.
National Institute on Alcohol  
Abuse and Alcoholism (NIAAA)
The National Institute on Alcohol Abuse and Alcoholism 
(NIAAA) provides leadership in the national effort to 
reduce alcohol-related problems by conducting and 
[]XXWZ\QVOZM[MIZKPQVI_QLMZIVOMWN [KQMV\QÅKIZMI[
including genetics, neuroscience, epidemiology, health 
ZQ[S[IVLJMVMÅ\[WN ITKWPWTKWV[]UX\QWVXZM^MV\QWV
and treatment; coordinating and collaborating with 
other research institutes and Federal programs on 
alcohol-related issues; collaborating with international, 
national, State, and local institutions, organizations, 
agencies, and programs engaged in alcohol-related work; 
IVL\ZIV[TI\QVOIVLLQ[[MUQVI\QVOZM[MIZKPÅVLQVO[
to healthcare providers, researchers, policymakers, 
and the public. Additional information is available 
at niaaa.nih.gov or by calling 301-443-3860.
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Selected Publications and Resources 
for Drug Addiction Treatment
The following are available from the NIDA DrugPubs 
Research Dissemination Center, the National Technical 
Information Service (NTIS), or the Government 
8ZQV\QVO7NÅKM/87<WWZLMZZMNMZ\W\PM,Z]O8]J[
(877-NIDANIH [643-2644]), NTIS (1-800-553-6847), or 
/87 V]UJMZXZW^QLML_Q\P\PMZM[W]ZKM
LM[KZQX\QWV"
Blending products61,)¼[*TMVLQVO1VQ\QI\Q^M¸I
RWQV\^MV\]ZM_Q\P;)50;)IVLQ\[VI\QWV_QLMVM\_WZS
WN )LLQK\QWV<MKPVWTWOa<ZIV[NMZ+MV\MZ[)<<+[¸
][M[¹*TMVLQVO<MIU[ºWN KWUU]VQ\aXZIK\Q\QWVMZ[
;)50;)\ZIQVMZ[IVL61,)ZM[MIZKPMZ[\WKZMI\M
XZWL]K\[IVLLM^Q[M[\ZI\MOQKLQ[[MUQVI\QWVXTIV[NWZ\PMU
+WUXTM\MLXZWL]K\[QVKT]LM\PW[M\PI\ILLZM[[\PM^IT]M
WN J]XZMVWZXPQVM\PMZIXaIVLWV[Q\MZIXQL01>\M[\QVO
QVKWUU]VQ\a\ZMI\UMV\XZWOZIU[#[\ZI\MOQM[NWZ\ZMI\QVO
XZM[KZQX\QWVWXQWQLLMXMVLMVKM#IVL\PMVMML\WMVPIVKM
PMIT\PKIZM_WZSMZ[¼XZWÅKQMVKaQV][QVO\WWT[[]KPI[\PM
)LLQK\QWV;M^MZQ\a1VLM`);1UW\Q^I\QWVITQV\MZ^QM_QVO
IVLUW\Q^I\QWVITQVKMV\Q^M[.WZUWZMQVNWZUI\QWV
WV*TMVLQVOXZWL]K\[XTMI[M^Q[Q\61,)¼[?MJ[Q\MI\
drugabuse.gov/blending-initiative
Addiction Severity Index8ZW^QLM[I[\Z]K\]ZMLKTQVQKIT
QV\MZ^QM_LM[QOVML\WKWTTMK\QVNWZUI\QWVIJW]\[]J[\IVKM
][MIVLN]VK\QWVQVOQVTQNMIZMI[NZWUIL]T\KTQMV\[[MMSQVO
LZ]OIJ][M\ZMI\UMV\.WZUWZMQVNWZUI\QWVWV][QVO\PM
);1IVL\WWJ\IQVKWXQM[WN \PMUW[\ZMKMV\MLQ\QWVXTMI[M
visit triweb.tresearch.org/index.php/tools/download-asi-
instruments-manuals/
National Institute of Mental Health 
(NIMH)
The mission of  the National Institute of  Mental Health 
6150Q[\W\ZIV[NWZU\PM]VLMZ[\IVLQVOIVL\ZMI\UMV\
WN UMV\ITQTTVM[[M[\PZW]OPJI[QKIVLKTQVQKITZM[MIZKP
XI^QVO\PM_IaNWZXZM^MV\QWVZMKW^MZaIVLK]ZM1V
support of  this mission, NIMH generates research 
IVLXZWUW\M[ZM[MIZKP\ZIQVQVO\WN]TÅTT\PMNWTTW_QVO
NW]ZWJRMK\Q^M["XZWUW\MLQ[KW^MZaQV\PMJZIQVIVL
behavioral sciences to fuel research on the causes of  
UMV\ITLQ[WZLMZ[#KPIZ\UMV\ITQTTVM[[\ZIRMK\WZQM[\W
LM\MZUQVM_PMV_PMZMIVLPW_\WQV\MZ^MVM#LM^MTWX
VM_IVLJM\\MZQV\MZ^MV\QWV[\PI\QVKWZXWZI\M\PMLQ^MZ[M
VMML[IVLKQZK]U[\IVKM[WN XMWXTM_Q\PUMV\ITQTTVM[[M[#
IVL[\ZMVO\PMV\PMX]JTQKPMIT\PQUXIK\WN 6150
[]XXWZ\MLZM[MIZKP)LLQ\QWVITQVNWZUI\QWVQ[I^IQTIJTMI\
nimh.nih.govWZJaKITTQVO
Center for Substance Abuse  
Treatment (CSAT)
The Center for Substance Abuse Treatment (CSAT), a 
XIZ\WN \PM;]J[\IVKM)J][MIVL5MV\IT0MIT\P;MZ^QKM[
)LUQVQ[\ZI\QWV;)50;)Q[ZM[XWV[QJTMNWZ[]XXWZ\QVO
\ZMI\UMV\[MZ^QKM[\PZW]OPIJTWKSOZIV\XZWOZIUI[
_MTTI[LQ[[MUQVI\QVOÅVLQVO[\W\PMÅMTLIVLXZWUW\QVO
\PMQZILWX\QWV+;)<IT[WWXMZI\M[\PMPW]Z6I\QWVIT
Treatment Referral Hotline (1-800-662-HELP), which 
WNNMZ[QVNWZUI\QWVIVLZMNMZZIT[MZ^QKM[\WXMWXTM
[MMSQVO\ZMI\UMV\XZWOZIU[IVLW\PMZI[[Q[\IVKM+;)<
X]JTQKI\QWV[IZMI^IQTIJTM\PZW]OP;)50;)¼[;\WZM 
(store.samhsa.gov)LLQ\QWVITQVNWZUI\QWVIJW]\+;)<
KIVJMNW]VLWV;)50;)¼[?MJ[Q\MI\samhsa.gov/about/
csat.aspx
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Alcohol Alert (published by NIAAA). This is a 
quarterly bulletin that disseminates important research 
ÅVLQVO[WVITKWPWTIJ][MIVLITKWPWTQ[U)^IQTIJTM 
online at niaaa.nih.gov/publications/journals-and-reports/
alcohol-alert.
Helping Patients Who Drink Too Much: A 
Clinician’s Guide (published by NIAAA). This booklet 
is written for primary care and mental health clinicians 
and provides guidance in screening and managing alcohol-
dependent patients. Available online at pubs.niaaa.nih.gov/
publications/Practitioner/CliniciansGuide2005/clinicians_
guide.htm.
Research Report Series: Therapeutic Community 
(2002). This report provides information on the role of  
residential drug-free settings and their role in the treatment 
process. NIH Publication #02-4877. Available online at 
drugabuse.gov/publications/research-reports/therapeutic-
community.
Drugs, Brains, and Behavior: The Science of 
Addiction (Reprinted 2010). This publication provides an 
overview of  the science behind the disease of  addiction. 
NIH Publication #10–5605. Available online at drugabuse.
gov/publications/science-addiction.
Seeking Drug Abuse Treatment: Know What To 
Ask (2011). This lay-friendly publication offers guidance in 
[MMSQVOLZ]OIJ][M\ZMI\UMV\IVLTQ[\[Å^MY]M[\QWV[\WI[S
when searching for a treatment program. NIH Publication 
#12-7764. Available online at drugabuse.gov/publications/
seeking-drug-abuse-treatment.
Principles of Drug Abuse Treatment for Criminal 
Justice Populations: A Research-Based Guide 
(Revised 2012). Provides 13 essential treatment principles 
and includes resource information and answers to 
frequently asked questions. NIH Publication No.: 11-5316. 
Available online at nida.nih.gov/PODAT_CJ.
NIDA DrugFacts: Treatment Approaches for Drug 
Addiction (Revised 2008). This is a fact sheet covering 
ZM[MIZKPÅVLQVO[WVMNNMK\Q^M\ZMI\UMV\IXXZWIKPM[NWZ
drug abuse and addiction. Available online at drugabuse.
gov/publications/drugfacts/treatment-approaches-drug-
addiction.
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Initiatives Designed to Move 
Treatment Research into Practice
Clinical Trials Network
Assessing the real-world effectiveness of  evidence-based 
treatments is a crucial step in bringing research to practice. 
Established in 1999, NIDA’s National Drug Abuse 
Treatment Clinical Trials Network (CTN) uses community 
settings with diverse patient populations and conditions 
to adjust and test protocols to meet the practical needs 
of  addiction treatment. Since its inception, the CTN 
has tested pharmacological and behavioral interventions 
for drug abuse and addiction, along with common 
co-occurring conditions (e.g., HIV and PTSD) among 
various target populations, including adolescent drug 
abusers, pregnant drug-abusing women, and Spanish-
speaking patients. The CTN has also tested prevention 
strategies in drug-abusing groups at high risk for HCV 
and HIV and has become a key element of  NIDA’s 
multipronged approach to move promising science-based 
drug addiction treatments rapidly into community settings. 
For more information on the CTN, please visit drugabuse.
gov/CTN/Index.htm. 
Criminal Justice–Drug Abuse 
Treatment Studies
NIDA is taking an approach similar to the CTN to 
enhance treatment for drug-addicted individuals involved 
with the criminal justice system through Criminal 
Justice–Drug Abuse Treatment Studies (CJ-DATS). 
Whereas NIDA’s CTN has as its overriding mission the 
improvement of  the quality of  drug abuse treatment by 
moving innovative approaches into the larger community, 
research supported through CJ-DATS is designed to 
effect change by bringing new treatment models into the 
criminal justice system and thereby improve outcomes for 
offenders with substance use disorders. It seeks to achieve 
better integration of  drug abuse treatment with other 
public health and public safety forums and represents a 
collaboration among NIDA; SAMHSA; the Centers for 
Disease Control and Prevention (CDC); Department of  
Justice agencies; and a host of  drug treatment, criminal 
justice, and health and social service professionals.
Blending Teams
Another way in which NIDA is seeking to actively move 
science into practice is through a joint venture with 
SAMHSA and its nationwide network of  Addiction 
Technology Transfer Centers (ATTCs). This process 
involves the collaborative efforts of  community treatment 
practitioners, SAMHSA trainers, and NIDA researchers, 
[WUMWN _PWUNWZU¹*TMVLQVO<MIU[º\WKZMI\M
products and devise strategic dissemination plans for 
them. Through the creation of  products designed to 
foster adoption of  new treatment strategies, Blending 
Teams are instrumental in getting the latest evidence-
based tools and practices into the hands of  treatment 
professionals. To date, a number of  products have been 
completed. Topics have included increasing awareness 
of  the value of  buprenorphine therapy and enhancing 
PMIT\PKIZM_WZSMZ[¼XZWÅKQMVKaQV][QVO\WWT[[]KPI[
the ASI, motivational interviewing, and motivational 
incentives. For more information on Blending products, 
please visit NIDA’s Web site at nida.nih.gov/blending.
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Other Federal Resources
NIDA DrugPubs Research Dissemination Center. 
NIDA publications and treatment materials are available 
from this information source. Staff  provide assistance 
in English and Spanish and have TTY/TDD capability. 
Phone: 877-NIDA-NIH (877-643-2644); TTY/TDD: 240-
645-0228; fax: 240-645-0227; e-mail: drugpubs@nida.nih.
gov; Web site: drugpubs.drugabuse.gov.
The National Registry of Evidence-Based Programs 
and Practices. This database of  interventions for the 
prevention and treatment of  mental and substance use 
disorders is maintained by SAMHSA and can be accessed 
at nrepp.samhsa.gov.
SAMHSA’s Store has a wide range of  products, 
including manuals, brochures, videos, and other 
publications. Phone: 800-487-4889; Web site:  
store.samhsa.gov.
The National Institute of Justice. As the research 
agency of  the U.S. Department of  Justice, the National 
Institute of  Justice (NIJ) supports research, evaluation, 
and demonstration programs relating to drug abuse in  
the context of  crime and the criminal justice system.  
For information, including a wealth of  publications, 
contact the National Criminal Justice Reference Service  
at 800-851-3420 or 301-519-5500; or visit nij.gov.
Clinical Trials. For more information on federally  
and privately supported clinical trials, please visit 
clinicaltrials.gov.
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